CUMULATIVE SUPPLEMENT 7
JAN'97-JUL'97



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DATABASE MANAGEMENT

Prepared By
Division of Database Management
Office of Management
Center for Drug Evaluation and Research, FDA

CONTENTS

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Cumulative Supplement 7

JULY 1997

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

CUMULATIVE SUPPLEMENT 7
JULY 1997

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 17th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 18th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA

applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 17th Edition that explains the background information on this court decision).

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP (CIBA GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP PHARMACEUTICALS DIV (CIBA GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
CIBA PHARMACEUTICAL CO DIV CIBA GEIGY CORP (CIBA)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
CIBA SELF MEDICATION INC DIV CIBA GEIGY CORP (CIBA)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
CIBA VISION OPHTHALMICS DIV CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
FERRING LABORATORIES INC (FERRING)	FERRING PHARMACEUTICALS INC (FERRING)
GEIGY PHARMACEUTICALS DIV CIBA GEIGY CORP (GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
LEMMON CO SUB TAG PHARMACEUTICAL INC (LEMMON)	BIOCRAFT LABORATORIES INC (BIOCRAFT) **THEN CHANGED TO** TEVA PHARMACEUTICALS USA (TEVA)
SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS (SANDOZ)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
SANDOZ PHARMACEUTICALS CORP DIV SANDOZ INC (SANDOZ)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
SANDOZ RESEARCH INSTITUTE INC (SANDOZ)	NOVARTIS PHARMACEUTCALS CORP (NOVARTIS)
SANOFI WINTHROP INC (SANOFI WINTHROP)	SANOFI PHARMACEUTICAL INC (SANOFI)
SURVIVAL TECHNOLOGY INC (SURVIVAL TECH)	MERIDIAN MEDICAL TECHNOLOGIES INC (MERIDIAN MEDCL TECHN)

1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novapharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1996*	MAR 1997	JUN 1997	SEP 1997
DRUG PRODUCTS LISTED	9392	9493	9533	
SINGLE SOURCE	2383 (25.4%)	2387 (25.1%)	2388 (25.0%)	
MULTISOURCE	6905 (73.5%)	6991 (73.7%)	7031 (73.8%)	
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6549 (69.0%)	6626 (69.5%)	
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	442 (4.7%)	405 (4.3%)	
EXCEPTIONS[1]	104 (1.1%)	115 (1.2%)	114 (1.2%)	
NEW MOLECULAR ENTITIES APPROVED	--	6	8	
NUMBER OF APPLICANTS	650	662	682	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions were no longer included in the Multisource Drug Products total count, but included in the total count of the Drug Products Listed.

ACARBOSE

TABLET; ORAL
PRECOSE

	BAYER	25MG	N20482 004 MAY 29, 1997

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE

AB	GRAHAM DM	325MG;50MG;40MG	N88743 001 JUL 18, 1985
AB		325MG;50MG;40MG	N88765 001 MAR 27, 1985
AB		325MG;50MG;40MG	N89067 001 APR 19, 1985
@		325MG;50MG;40MG	N88743 001 JUL 18, 1985
@		325MG;50MG;40MG	N88765 001 MAR 27, 1985
@		325MG;50MG;40MG	N89067 001 APR 19, 1985

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	EON	500MG;5MG	N40149 001 JAN 27, 1997
AA		750MG;7.5MG	N40149 002 JAN 27, 1997
AA	VINTAGE PHARMS	500MG;2.5MG	N40144 002 APR 25, 1997
AA		650MG;7.5MG	N40155 001 APR 14, 1997
AA	WATSON LABS	500MG;10MG	N40148 002 FEB 14, 1997

LORTAB

AA +	GRAHAM DM	500MG;10MG	N40100 001 JAN 26, 1996
AA +	UCB	500MG;10MG	N40100 001 JAN 26, 1996
		325MG;5MG	N40099 001 JUN 25, 1997

NORCO

+	WATSON LABS	325MG;10MG	N40148 001 FEB 14, 1997

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	VINTAGE PHARMS	650MG;100MG	N74843 001 FEB 12, 1997

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

AB	TARO	125MG	N40195 001 MAY 28, 1997
AB		250MG	N40195 002 MAY 28, 1997

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC
TRIDESILON

	BAYER	2%;0.05%	N17914 001
@		2%;0.05%	N17914 001

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	AESGEN	200MG	N74833 001 APR 22, 1997
AB	ESI LEDERLE	200MG	N74872 001 APR 22, 1997
AB	LEK PHARM	200MG	N74750 001 APR 22, 1997
AB	LEMMON	200MG	N74828 001 APR 22, 1997
AB	MYLAN	200MG	N74727 001 APR 22, 1997
AB	NOVOPHARM	200MG	N74578 001 APR 22, 1997
AB	ROXANE	200MG	N74570 002 APR 22, 1997
AB	TEVA	200MG	N74828 001 APR 22, 1997
AB	ZENITH GOLDLINE	200MG	N74674 001 APR 22, 1997

ACYCLOVIR

CAPSULE; ORAL

	ZOVIRAX			
AB	+ GLAXO WELLCOME	200MG	N18828 001	JAN 25, 1985

SUSPENSION; ORAL

	ACYCLOVIR			
AB	ALPHARMA	200MG/5ML	N74738 001	APR 28, 1997
	ZOVIRAX			
AB	+ GLAXO WELLCOME	200MG/5ML	N19909 001	DEC 22, 1989

TABLET; ORAL

	ACYCLOVIR			
AB	ESI LEDERLE	400MG	N74834 001	APR 24, 1997
AB		800MG	N74834 002	APR 24, 1997
AB	LEK PHARM	400MG	N74658 001	APR 22, 1997
AB		800MG	N74658 002	APR 22, 1997
AB	NOVOPHARM	400MG	N74556 002	APR 22, 1997
AB		800MG	N74556 003	APR 22, 1997
	+	200MG	N74556 001	APR 22, 1997
AB	PUREPAC PHARM	400MG	N74870 001	JUN 05, 1997
AB		800MG	N74870 002	JUN 05, 1997
AB	ZENITH GOLDLINE	400MG	N74836 001	APR 22, 1997
AB		800MG	N74836 002	APR 22, 1997
	ZOVIRAX			
AB	GLAXO WELLCOME	400MG	N20089 001	APR 30, 1991
AB	+	800MG	N20089 002	APR 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ACYCLOVIR SODIUM			
AP	ABBOTT	EQ 500MG BASE/VIAL	N74663 001	APR 22, 1997
AP		EQ 500MG BASE/VIAL	N74758 001	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74663 002	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74758 002	APR 22, 1997
AP	BEDFORD	EQ 500MG BASE/VIAL	N74596 002	APR 22, 1997
AP		EQ 1GM BASE/VIAL	N74596 001	APR 22, 1997
	+ FAULDING	EQ 25MG BASE/ML	N74720 001	APR 22, 1997
	ZOVIRAX			
AP	+ GLAXO WELLCOME	EQ 500MG BASE/VIAL	N18603 001	OCT 22, 1982
AP	+	EQ 1GM BASE/VIAL	N18603 002	JUN 29, 1989

ALENDRONATE SODIUM

TABLET; ORAL

	FOSAMAX			
	MERCK	EQ 5MG BASE	N20560 003	APR 25, 1997

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM			
AB	ROYCE LABS	0.25MG	N74479 001	JAN 21, 1997
AB		0.5MG	N74479 002	JAN 21, 1997
AB		1MG	N74479 003	JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT

AP		PHARMACIA AND UPJOHN	0.005MG/VIAL	N20379 003 JUN 27, 1996
AP			0.01MG/VIAL	N20379 001 JUL 06, 1995
AP			0.02MG/VIAL	N20379 002 JUL 06, 1995
AP	+		0.04MG/VIAL	N20379 004 MAY 19, 1997

EDEX

AP		SCHWARZ PHARMA	0.005MG/VIAL	N20649 001 JUN 12, 1997
AP			0.01MG/VIAL	N20649 002 JUN 12, 1997
AP			0.02MG/VIAL	N20649 003 JUN 12, 1997
AP	+		0.04MG/VIAL	N20649 004 JUN 12, 1997

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

AP		ELKINS SINN	EQ 50MG BASE/ML	N63274 001 MAY 18, 1992
	@		EQ 50MG BASE/ML	N63274 001 MAY 18, 1992

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		ABBOTT	EQ 500MG BASE/100ML	N64146 001 APR 02, 1997

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN II 5%

		ABBOTT	5%	N19438 002 APR 03, 1986
	@		5%	N19438 002 APR 03, 1986

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

		ABBOTT	5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 004 NOV 07, 1988
	@		5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 004 NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 002 MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 005 MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 001 MAR 26, 1997

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML	N20678 009 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 4.25%;33MG/100ML;20GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML — N20678 011 — MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 4.25%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML — N20678 012 — MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 4.25%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML — N20678 008 — MAR 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

> DLT >
> DLT >
> ADD >
> ADD >

+ BAXTER HLTHCARE — 5%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML — N20678 016 — MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;15GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML — N20678 017 — MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML — N20678 018 — MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML — N20678 019 — MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;35GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML — N20678 021 — MAR 26, 1997

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLIN

AP + SEARLE — 25MG/ML — N87243 001 — MAY 24, 1982

@ — 25MG/ML — N87243 001 — MAY 24, 1982

AMINOPHYLLINE

AP ELKINS SINN — 25MG/ML — N87239 001

AP + — 25MG/ML — N87239 001

AP PHARMA SERVE NY — 25MG/ML — N87387 001 — JUN 03, 1983

@ — 25MG/ML — N87387 001 — JUN 03, 1983

TABLET; ORAL

AMINOPHYLLINE

BD HALSEY — 100MG — N84674 001

@ — 100MG — N84674 001

TABLET, EXTENDED RELEASE; ORAL

PHYLLOCONTIN

+ PURDUE FREDERICK — 225MG — N86760 001

@ — 225MG — N86760 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

BP HALSEY — 10MG — N85923 001

BP — 50MG — N85925 001

BP — 75MG — N85926 001 — MAY 20, 1983

BP — 100MG — N85927 001 — MAY 20, 1983

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

	@	HALSEY	10MG	N85923 001
	@		50MG	N85925 001
	@		75MG	N85926 001 MAY 20, 1983
	@		100MG	N85927 001 MAY 20, 1983

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
LIMBITROL

AB	+	ROCHE	EQ 25MG BASE;10MG	N16949 002

LIMBITROL DS

AB	+	ROCHE	EQ 25MG BASE;10MG	N16949 002

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
ETRAFON-A

BP		SCHERING	10MG;4MG	N14713 002
	@		10MG;4MG	N14713 002

AMOXICILLIN

CAPSULE; ORAL
AMOXIL

AB	+	SMITHKLINE BEECHAM	250MG	N50459 001
AB			250MG	N62216 001
AB	+		250MG	N62216 001
AB	+		500MG	N50459 002
AB			500MG	N62216 004
AB	+		500MG	N62216 004
	@		250MG	N50459 001
	@		500MG	N50459 002

POWDER FOR RECONSTITUTION; ORAL
AMOXIL

AB	+	SMITHKLINE BEECHAM	125MG/5ML	N50460 001
AB			125MG/5ML	N62226 001
AB	+		125MG/5ML	N62226 001
AB	+		250MG/5ML	N50460 002
AB	+		50MG/ML	N50460 005

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL
AMOXIL

AB		SMITHKLINE BEECHAM	250MG/5ML	N62226 002
AB	+		250MG/5ML	N62226 002
AB			50MG/ML	N62226 005
AB	+		50MG/ML	N62226 005
	@		125MG/5ML	N50460 001
	@		250MG/5ML	N50460 002
	@		50MG/ML	N50460 005

LAROTID

AB		SMITHKLINE BEECHAM	50MG/ML	N50460 006
	@		50MG/ML	N50460 006

AMPHOTERICIN B

OINTMENT; TOPICAL
FUNGIZONE

	+	APOTHECON	3%	N50313 001
	@		3%	N50313 001

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL
AGRYLIN

		ROBERTS LABS	EQ 0.5MG BASE	N20333 001 MAR 14, 1997
	+		EQ 1MG BASE	N20333 002 MAR 14, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION
NORMIFLO

	+	WYETH AYERST	5,000 UNITS/0.5ML	N20227 002 MAY 23, 1997
	+		10,000 UNITS/0.5ML	N20227 001 MAY 23, 1997

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL

	+	SAVAGE LABS	650MG;50MG	N88305 001 OCT 13, 1983

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL

@	SAVAGE LABS	650MG;50MG	N88305 001	OCT 13, 1983

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
CODOXY

AA	HALSEY	325MG;4.5MG;0.38MG	N87464 001	JUL 01, 1982
@		325MG;4.5MG;0.38MG	N87464 001	JUL 01, 1982

ATENOLOL

TABLET; ORAL
ATENOLOL

>ADD<	AB	MUTUAL PHARM	25MG	N74499 001	JUL 30, 1997
>ADD<	AB	SIDMAK LABS NJ	25MG	N74101 001	JUL 17, 1997
>ADD<	AB		50MG	N74101 002	JUL 17, 1997
>ADD<	AB		100MG	N74101 003	JUL 17, 1997

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

AP	ABBOTT	10MG/ML	N74633 001	DEC 23, 1996
>ADD< AP	BEDFORD	10MG/ML	N74901 001	JUL 18, 1997
AP	FAULDING	10MG/ML	N74740 001	MAR 28, 1997
AP	GENSIA	10MG/ML	N74784 001	JUN 11, 1997
AP	OHMEDA	10MG/ML	N74753 001	JAN 23, 1997

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	ABBOTT	10MG/ML	N74633 001	DEC 23, 1996

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	ABBOTT	10MG/ML	N74639 001	MAR 25, 1997
>ADD< AP	BEDFORD	10MG/ML	N74900 001	JUL 18, 1997
AP	FAULDING	10MG/ML	N74741 001	MAR 28, 1997
AP	OHMEDA	10MG/ML	N74768 001	JAN 23, 1997

TRACRIUM

AP	+	GLAXO WELLCOME	10MG/ML	N18831 001	NOV 23, 1983
AP	+		10MG/ML	N18831 002	JUN 20, 1985

TRACRIUM PRESERVATIVE FREE

AP	+	GLAXO WELLCOME	10MG/ML	N18831 001	NOV 23, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

AA	ROXANE	0.025MG;2.5MG	N86057 001	
@		0.025MG;2.5MG	N86057 001	

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

>DLT< AA	ICN	0.025MG;2.5MG	N87195 001	FEB 16, 1982
>DLT< >ADD<	@	0.025MG;2.5MG	N87195 001	FEB 16, 1982
AA	KV PHARM	0.025MG;2.5MG	N85659 001	
@		0.025MG;2.5MG	N85659 001	

AZITHROMYCIN DIHYDRATE

INJECTABLE; INJECTION
ZITHROMAX

+	PFIZER	EQ 500MG BASE/VIAL	N50733 001	JAN 30, 1997

BACITRACIN

INJECTABLE; INJECTION

		BACIIM		
AP		PHARMA TEK	50,000 UNITS/VIAL	N64153 001 MAY 09, 1997
		BACITRACIN		
AP	+	PHARMACIA AND UPJOHN	50,000 UNITS/VIAL	N60733 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

		CORTISPORIN		
	+	GLAXO WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002 MAY 04, 1984
	+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002 MAY 04, 1984

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

		BECONASE AQ		
BN		GLAXO WELLCOME	EQ 0.042MG DIPROP/SPRAY	N19389 001 JUL 27, 1987
BN	+		EQ 0.042MG DIPROP/SPRAY	N19389 001 JUL 27, 1987

BENZQUINAMIDE HYDROCHLORIDE

SUPPOSITORY; RECTAL

> DLT >		EMETE-CON		
> DLT >	+	ROERIG	EQ 100MG BASE	N16818 006
> ADD >	@		EQ 100MG BASE	N16818 006

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

		BETAMETHASONE DIPROPIONATE		
> ADD >	@	ALPHARMA	EQ 0.05% BASE	N71085 001 FEB 03, 1987
> ADD >				
> DLT >	AB	NMC	EQ 0.05% BASE	N71085 001 FEB 03, 1987
> DLT >				

BETAMETHASONE VALERATE

CREAM; TOPICAL

		BETAMETHASONE VALERATE		
AB		FOUGERA	EQ 0.1% BASE	N18861 001 AUG 31, 1983
AB	+		EQ 0.1% BASE	N18861 001 AUG 31, 1983
		VALISONE		
AB	+	SCHERING	EQ 0.1% BASE	N16322 001
			EQ 0.01% BASE	N16322 002
	@		EQ 0.01% BASE	N16322 002
	@		EQ 0.1% BASE	N16322 001

LOTION; TOPICAL

		BETAMETHASONE VALERATE		
AB		FOUGERA	EQ 0.1% BASE	N18866 001 AUG 31, 1983
AB	+		EQ 0.1% BASE	N18866 001 AUG 31, 1983
		VALISONE		
AB	+	SCHERING	EQ 0.1% BASE	N16932 001
	@		EQ 0.1% BASE	N16932 001

OINTMENT; TOPICAL

		BETAMETHASONE VALERATE		
AB		FOUGERA	EQ 0.1% BASE	N18865 001 AUG 31, 1983
AB	+		EQ 0.1% BASE	N18865 001 AUG 31, 1983
		VALISONE		
AB	+	SCHERING	EQ 0.1% BASE	N16740 001
	@		EQ 0.1% BASE	N16740 001

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

		BETOPTIC PILO		
	+	ALCON	EQ 0.25% BASE;1.75%	N20619 001 APR 17, 1997

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

		BLENOXANE		
AP	+	BRISTOL MYERS SQUIBB	EQ 30 UNITS BASE/VIAL	N50443 002 SEP 07, 1995

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP		PHARMACIA AND UPJOHN	**EQ 30 UNITS BASE/VIAL**	**N64084 002** JUN 01, 1996
	+		EQ 30 UNITS BASE/VIAL	N64084 002 JUN 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	200MG/100ML	N19837 002 APR 12, 1989
AP	+		400MG/100ML	N19837 001 APR 12, 1989
	@		200MG/100ML	N19837 002 APR 12, 1989
	@		400MG/100ML	N19837 001 APR 12, 1989

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN

	+	ALLERGAN	0.5%	N20490 001 MAR 13, 1997

> ADD > BROMFENAC SODIUM

> ADD > CAPSULE; OPHTHALMIC
> ADD > DURACT

> ADD >	+	WYETH AYERST	EQ 25MG BASE	N20535 001 JUL 15, 1997

BUDESONIDE

AEROSOL, METERED; NASAL
RHINOCORT

	+	ASTRA	0.05MG/INH	N20233 001 FEB 14, 1994
	+		0.032MG/INH	N20233 001 FEB 14, 1994

BUDESONIDE

POWDER, METERED; INHALATION
PULMICORT

+	ASTRA	0.16MG/INH	N20441 002 JUN 24, 1997
@		0.32MG/INH	N20441 003 JUN 24, 1997

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN

+	GLAXO WELLCOME	100MG	N20358 002 OCT 04, 1996
+		150MG	N20358 003 OCT 04, 1996

ZYBAN

	GLAXO WELLCOME	100MG	N20711 002 MAY 14, 1997
		150MG	N20711 003 MAY 14, 1997
+		100MG	N20711 002 MAY 14, 1997
+		150MG	N20711 003 MAY 14, 1997

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT ONE

+	ROCHE	2%	N19881 001 FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	ABBOTT	**1MG/ML**	**N74620 001** JAN 22, 1997
AP		**1MG/ML**	**N74626 001** JAN 23, 1997
AP		**2MG/ML**	**N74620 002** JAN 22, 1997
AP		**2MG/ML**	**N74626 002** JAN 23, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

		STADOL		
AP	+	APOTHECON	2MG/ML	N17857 004
		STADOL PRESERVATIVE FREE		
AP	+	APOTHECON	1MG/ML	N17857 001
AP	+		2MG/ML	N17857 002

CALCIPOTRIENE

SOLUTION; TOPICAL

		DOVONEX		
	+	BRISTOL MYERS SQUIBB	0.005%	N20611 001 MAR 03, 1997

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

		DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER		
		MCGAW	4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML	N19634 002 FEB 24, 1988
	@		4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML	N19634 002 FEB 24, 1988
		DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER		
AP		MCGAW	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N17510 001
	@		20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N17510 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

		LACTATED RINGER'S IN PLASTIC CONTAINER		
AP		MCGAW	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001
	@		20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001

CAPTOPRIL

TABLET; ORAL

		CAPOTEN		
AB	+	BRISTOL MYERS SQUIBB	25MG	N18343 002
AB			25MG	N18343 002
		CAPTOPRIL		
AB		EGIS PHARMS	12.5MG	N74748 004 MAY 29, 1997
AB			25MG	N74748 002 MAY 29, 1997
AB			50MG	N74748 001 MAY 29, 1997
AB			100MG	N74748 003 MAY 29, 1997
AB		PUREPAC PHARM	12.5MG	N74640 001 MAR 31, 1997
AB			25MG	N74640 002 MAR 31, 1997
AB			50MG	N74640 003 MAR 31, 1997
AB			100MG	N74640 004 MAR 31, 1997
AB		STASON	12.5MG	N74677 004 MAY 30, 1997
AB			25MG	N74677 002 MAY 30, 1997
AB			50MG	N74677 001 MAY 30, 1997
AB			100MG	N74677 003 MAY 30, 1997
AB		WOCKHARDT	12.5MG	N74532 001 MAR 28, 1997
AB			25MG	N74532 002 MAR 28, 1997
AB			50MG	N74532 003 MAR 28, 1997
AB			100MG	N74532 004 MAR 28, 1997

CARBAMAZEPINE

TABLET; ORAL

		EPITOL		
AB		LEMMON	200MG	N70541 001 SEP 17, 1986
AB		TEVA	200MG	N70541 001 SEP 17, 1986

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

	EPITOL			
AB	LEMMON	**100MG**	**N73524 001**	JUL 29, 1992
AB	TEVA	**100MG**	**N73524 001**	JUL 29, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL

	CARBIDOPA AND LEVODOPA			
AB	LEMMON	**10MG;100MG**	**N73618 001**	AUG 28, 1992
AB		**25MG;100MG**	**N73589 001**	AUG 28, 1992
AB		**25MG;250MG**	**N73607 001**	AUG 28, 1992
AB	TEVA	**10MG;100MG**	**N73618 001**	AUG 28, 1992
AB		**25MG;100MG**	**N73589 001**	AUG 28, 1992
AB		**25MG;250MG**	**N73607 001**	AUG 28, 1992

CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL			
AA	AMIDE PHARM	**350MG**	**N40188 001**	MAR 07, 1997

CARVEDILOL

TABLET; ORAL

	COREG			
	SMITHKLINE BEECHAM	3.125MG	N20297 004	MAY 29, 1997

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	LEMMON	**EQ 250MG BASE/VIAL**	**N63016 001**	MAR 14, 1989

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	LEMMON	**EQ 500MG BASE/VIAL**	**N63016 002**	MAR 14, 1989
AP		**EQ 1GM BASE/VIAL**	**N63016 003**	MAR 14, 1989
AP		**EQ 5GM BASE/VIAL**	**N63018 001**	MAR 05, 1990
AP		**EQ 10GM BASE/VIAL**	**N63018 002**	MAR 05, 1990
AP	TEVA	**EQ 250MG BASE/VIAL**	**N63016 001**	MAR 14, 1989
AP		**EQ 500MG BASE/VIAL**	**N63016 002**	MAR 14, 1989
AP		**EQ 1GM BASE/VIAL**	**N63016 003**	MAR 14, 1989
AP		**EQ 5GM BASE/VIAL**	**N63018 001**	MAR 05, 1990
AP		**EQ 10GM BASE/VIAL**	**N63018 002**	MAR 05, 1990

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL

	CEFTIN			
+	GLAXO WELLCOME	EQ 125MG BASE/5ML	N50672 001	JUN 30, 1994
		EQ 125MG BASE/5ML	N50672 001	JUN 30, 1994
+		EQ 250MG BASE/5ML	N50672 002	APR 29, 1997

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	CEFUROXIME SODIUM			
AB	HANFORD GC	**EQ 750MG BASE/VIAL**	**N64125 001**	MAY 30, 1997
AP		**EQ 1.5GM BASE/VIAL**	**N64125 002**	MAY 30, 1997
AP		**EQ 7.5GM BASE/VIAL**	**N64124 001**	MAY 30, 1997
	KEFUROX			
AB	LILLY	**EQ 750MG BASE/VIAL**	**N62591 001**	JAN 10, 1986

CEFUROXIME SODIUM

INJECTABLE; INJECTION
KEFUROX
AB LILLY EQ 750MG BASE/VIAL N62592 001 JAN 10, 1986
AP EQ 750MG BASE/VIAL N62591 001 JAN 10, 1986
AP EQ 750MG BASE/VIAL N62592 001 JAN 10, 1986

ZINACEF
AB + GLAXO WELLCOME EQ 750MG BASE/VIAL N50558 002 OCT 19, 1983
AP + EQ 750MG BASE/VIAL N50558 002 OCT 19, 1983

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN
AB APOTHECON EQ 250MG BASE N62973 001 NOV 08, 1988
AB EQ 500MG BASE N62974 001 NOV 23, 1988
@ EQ 250MG BASE N62973 001 NOV 08, 1988
@ EQ 500MG BASE N62974 001 NOV 23, 1988
AB PUREPAC PHARM EQ 250MG BASE N62809 001 APR 22, 1987
AB EQ 500MG BASE N62809 002 APR 22, 1987
@ EQ 250MG BASE N62809 001 APR 22, 1987
@ EQ 500MG BASE N62809 002 APR 22, 1987

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL
APOTHECON EQ 1GM BASE/VIAL N62724 001 DEC 23, 1986
EQ 2GM BASE/VIAL N62724 002 DEC 23, 1986
@ EQ 1GM BASE/VIAL N62724 001 DEC 23, 1986

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL
@ APOTHECON EQ 2GM BASE/VIAL N62724 002 DEC 23, 1986

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL
@ BAYER 0.05MG N20740 001 JUN 26, 1997
@ 0.1MG N20740 002 JUN 26, 1997
0.2MG N20740 003 JUN 26, 1997
+ 0.3MG N20740 004 JUN 26, 1997

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT
+ PARKE DAVIS 10MG/GM;5MG/GM; 10,000 UNITS/GM N50201 002
@ 10MG/GM;5MG/GM; 10,000 UNITS/GM N50201 002

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL
CHLOROMYCETIN PALMITATE
PARKE DAVIS EQ 150MG BASE/5ML N62301 001
@ EQ 150MG BASE/5ML N62301 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS
ROCHE 10MG N85481 001
@ 10MG N85481 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	LEMMON	0.12%	N74522 001	DEC 15, 1995
AT	TEVA	0.12%	N74522 001	DEC 15, 1995

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NESACAINE-MPF

AP	+ ASTRA	2%	N09435 003	
AP	+	2%	N09435 006	MAY 02, 1996
AP	+	3%	N09435 004	
AP	+	3%	N09435 007	MAY 02, 1996
	@	2%	N09435 003	
	@	3%	N09435 004	

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA	KV PHARM	4MG	N87164 001	
	@	4MG	N87164 001	
	KLOROMIN			
AA	HALSEY	4MG	N83629 001	
	@	4MG	N83629 001	

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

	@ LEMMON	50MG	N88651 001	MAY 30, 1985	
>DLT> AB	PUREPAC PHARM	50MG	N88140 001	AUG 11, 1983	
>DLT>					
>ADD>	@	50MG	N88140 001	AUG 11, 1983	
>ADD>					
	@ TEVA	50MG	N88651 001	MAY 30, 1985	
	THALITONE				
BX	HORUS THERAP	25MG	N88051 001	NOV 12, 1982	

CHLORTHALIDONE

TABLET; ORAL
THALITONE

	+ HORUS THERAP	15MG	N19574 001	DEC 20, 1988
BX	MONARCH PHARMS	25MG	N19574 002	FEB 12, 1992
	+	15MG	N19574 001	DEC 20, 1988
	@	25MG	N88051 001	NOV 12, 1982

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	LEMMON	500MG	N89859 001	MAY 04, 1988
AA	TEVA	500MG	N89859 001	MAY 04, 1988

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE

>ADD> AB	BAKER NORTON	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
>ADD>				
>ADD> AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
>ADD>				

>ADD> CICLOPIROX

>ADD> GEL; TOPICAL
>ADD> LOPROX
>ADD> + HOECHST MARION RSSL 0.77% N20519 001 JUL 21, 1997
>ADD>

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	LEMMON	200MG	N74365 001	FEB 28, 1995

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	LEMMON	300MG	N74365 002 FEB 28, 1995	
AB		400MG	N74365 003 FEB 28, 1995	
AB		800MG	N74365 004 FEB 28, 1995	
AB	SIDMAK LABS NJ	200MG	N74568 001 FEB 27, 1997	
AB		300MG	N74568 002 FEB 27, 1997	
AB		400MG	N74568 003 FEB 27, 1997	
AB		800MG	N74566 001 FEB 27, 1997	
AB	TEVA	200MG	N74365 001 FEB 28, 1995	
AB		300MG	N74365 002 FEB 28, 1995	
AB		400MG	N74365 003 FEB 28, 1995	
AB		800MG	N74365 004 FEB 28, 1995	

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	SANOFI	EQ 300MG BASE/2ML	N74296 001 MAR 28, 1997	
AP		EQ 300MG BASE/2ML	N74412 001 MAR 28, 1997	> ADD > > ADD >

SOLUTION; ORAL
CIMETIDINE HCL

AA	PHARM ASSOC	EQ 300MG BASE/5ML	N74553 001 JAN 27, 1997	

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	LEMMON	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994	

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	TEVA	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994	

TABLET; ORAL
CLEMASTINE FUMARATE

AB	LEMMON	2.68MG	N73283 001 JAN 31, 1992	
	@	1.34MG	N73282 001 JAN 31, 1992	
AB	TEVA	2.68MG	N73283 001 JAN 31, 1992	
	@	1.34MG	N73282 001 JAN 31, 1992	

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	QUAD PHARMS	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987	
	@	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987	

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT	FOUGERA	EQ 1% BASE	N64159 001 JUN 05, 1997	
AT	LEMMON	EQ 1% BASE	N62930 001 JUN 28, 1989	
AT	MORTON GROVE	EQ 1% BASE	N63304 001 JUL 15, 1997	
AT	TEVA	EQ 1% BASE	N62930 001 JUN 28, 1989	

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CORMAX

AB	HEALTHPOINT	0.05%	N74220 001 MAY 16, 1997

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB	INVAMED	25MG	N74953 001	JUN 25, 1997
AB		50MG	N74953 002	JUN 25, 1997
AB		75MG	N74953 003	JUN 25, 1997
AB	NOVOPHARM	25MG	N74849 001	APR 04, 1997
AB		50MG	N74849 002	APR 04, 1997
AB		75MG	N74849 003	APR 04, 1997

CLONAZEPAM

TABLET; ORAL
KLONOPIN

+	ROCHE	0.125MG	N17533 005	APR 09, 1997
		0.25MG	N17533 006	APR 09, 1997

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

AB	PUREPAC PHARM	7.5MG	N71925 001	APR 25, 1988
AB		15MG	N71926 001	APR 25, 1988
@		7.5MG	N71925 001	APR 25, 1988
@		15MG	N71926 001	APR 25, 1988

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHERAZINE W/ CODEINE

AA	HALSEY	10MG/5ML;6.25MG/5ML	N88739 001	DEC 23, 1988

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHERAZINE W/ CODEINE

@	HALSEY	10MG/5ML;6.25MG/5ML	N88739 001	DEC 23, 1988

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION
INTAL

+	FISONS	0.8MG/INH	N18887 001	DEC 05, 1985
+	RHONE POULENC RORER	0.8MG/INH	N18887 001	DEC 05, 1985

CAPSULE; INHALATION
INTAL

+	FISONS	20MG	N16990 001
+	RHONE POULENC RORER	20MG	N16990 001

SOLUTION; INHALATION
INTAL

AN	+ FISONS	10MG/ML	N18596 001	MAY 28, 1982
AN	+ RHONE POULENC RORER	10MG/ML	N18596 001	MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC
OPTICROM

@	FISONS	4%	N18155 001	OCT 03, 1984
@	RHONE POULENC RORER	4%	N18155 001	OCT 03, 1984

SPRAY, METERED; NASAL
NASALCROM

+	FISONS	5.2MG/SPRAY	N18306 001	MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION
COBAVITE

AP	STERIS	0.1MG/ML	N83013 001	
AP		1MG/ML	N83064 001	
@		0.1MG/ML	N83013 001	

CYANOCOBALAMIN

INJECTABLE; INJECTION

	COBAVITE			
	@ STERIS	1MG/ML	N83064 001	
	CYANOCOBALAMIN			
AP	STERIS	0.1MG/ML	N83120 001	
	@	0.1MG/ML	N83120 001	

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A

DICOPAC KIT			
AMERSHAM	N/A;N/A;N/A	N17406 001	
MEDI PHYSICS	N/A;N/A;N/A	N17406 001	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AK-PENTOLATE			
AT	AKORN	1%	N85555 001	
	@	1%	N85555 001	
	AKPENTOLATE			
AT	AKORN	1%	N40164 001	JAN 13, 1997
AT		2%	N40165 001	JAN 13, 1997
	CYCLOGYL			
AT +	ALCON	2%	N84108 001	

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	CYCLOPHOSPHAMIDE			
AP	ASTA	100MG/VIAL	N88371 001	JUL 03, 1986
AP		200MG/VIAL	N88372 001	JUL 03, 1986
AP		500MG/VIAL	N88373 001	JUL 03, 1986
AP		1GM/VIAL	N88374 001	SEP 24, 1986
AP	ELKINS SINN	100MG/VIAL	N88371 001	JUL 03, 1986
AP		200MG/VIAL	N88372 001	JUL 03, 1986

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	CYCLOPHOSPHAMIDE			
AP	ELKINS SINN	500MG/VIAL	N88373 001	JUL 03, 1986
AP		1GM/VIAL	N88374 001	SEP 24, 1986
	CYTOXAN			
AP +	BRISTOL MYERS SQUIBB	100MG/VIAL	N12142 001	
AP +		200MG/VIAL	N12142 002	
AP +		500MG/VIAL	N12142 003	
AP +		1GM/VIAL	N12142 004	AUG 30, 1982
AP +		2GM/VIAL	N12142 005	AUG 30, 1982
	@	100MG/VIAL	N12142 001	
	@	200MG/VIAL	N12142 002	
	@	500MG/VIAL	N12142 003	
	@	1GM/VIAL	N12142 004	AUG 30, 1982
	@	2GM/VIAL	N12142 005	AUG 30, 1982

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

	CYPROHEPTADINE HCL			
AA	HALSEY	4MG	N89057 001	JUL 03, 1986
	@	4MG	N89057 001	JUL 03, 1986

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	CERUBIDINE			
AP	RHONE POULENC RORER	EQ 20MG BASE/VIAL	N61876 001	
	@	EQ 20MG BASE/VIAL	N61876 001	
AP +	WYETH AYERST	EQ 20MG BASE/VIAL	N50484 001	
	@	EQ 20MG BASE/VIAL	N50484 001	
	DAUNORUBICIN HCL			
AP	BEDFORD	EQ 20MG BASE/VIAL	N64103 001	FEB 03, 1995
+		EQ 20MG BASE/VIAL	N64103 001	FEB 03, 1995

DELAVIRDINE MESYLATE

TABLET; ORAL
RESCRIPTOR
+ PHARMACIA AND UPJOHN 100MG — N20705 001 APR 04, 1997

DESERPIDINE

TABLET; ORAL
HARMONYL
+ ABBOTT 0.25MG — N10796 002
@ 0.25MG — N10796 002

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB SIDMAK LABS NJ **100MG** — **N71803 001 MAY 29, 1997**
AB **150MG** — **N71804 001 MAY 29, 1997**

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE
>DLT> **AA** **ALPHARMA** **0.5MG/5ML** — **N88997 001 OCT 10, 1986**
>DLT>
>ADD> @ 0.5MG/5ML — N88997 001 OCT 10, 1986
>ADD>

GEL; TOPICAL
DECADERM
+ MERCK SHARP DOHME 0.1% — N13538 001
@ 0.1% — N13538 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
>DLT> **DEXASPORIN**
>DLT> **AT** **BAUSCH AND LOMB** **0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM** — **N64063 001 JUL 25, 1994**
>DLT>
>DLT>

>ADD>
>ADD> **AT** **NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE**
>ADD> **BAUSCH AND LOMB** **0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM** — **N64063 001 JUL 25, 1994**
>ADD>

DEXAMETHASONE SODIUM PHOSPHATE

CREAM; TOPICAL
DECADRON
+ MERCK SHARP DOHME EQ 0.1% PHOSPHATE — N11983 002
@ EQ 0.1% PHOSPHATE — N11983 002

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
AP STERIS **EQ 4MG PHOSPHATE/ML** — **N84355 001**
@ EQ 4MG PHOSPHATE/ML — N84355 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW 5GM/100ML;37MG/100ML — **N19699 001 SEP 29, 1989**
@ 5GM/100ML;37MG/100ML — N19699 001 SEP 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW **5GM/100ML;75MG/100ML** — **N19699 002 SEP 29, 1989**
@ 5GM/100ML;75MG/100ML — N19699 002 SEP 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW 5GM/100ML;110MG/100ML — **N19699 003 SEP 29, 1989**
@ 5GM/100ML;110MG/100ML — N19699 003 SEP 29, 1989
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW 5GM/100ML;220MG/100ML — **N19699 005 SEP 29, 1989**
@ 5GM/100ML;220MG/100ML — N19699 005 SEP 29, 1989

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> DLT >	AP	MCGAW	10GM/100ML;900MG/100ML	N18047 001
> ADD >		@	10GM/100ML;900MG/100ML	N18047 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	AP	MCGAW	5GM/100ML;900MG/100ML	N18026 001
		@	5GM/100ML;900MG/100ML	N18026 001

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

KNOLL PHARM	1MG		N12302 005
	2MG		N12302 002
+	4MG		N12302 004
@	1MG		N12302 005
@	2MG		N12302 002
@	4MG		N12302 004

DIAZEPAM

> ADD > GEL; RECTAL

> ADD > DIASTAT

> ADD >	+ ATHENA	2.5MG/0.5ML	N20648 001
> ADD >			JUL 29, 1997
> ADD >		5MG/ML	N20648 002
> ADD >			JUL 29, 1997
> ADD >		10MG/2ML	N20648 003
> ADD >			JUL 29, 1997
> ADD >		15MG/3ML	N20648 004
> ADD >			JUL 29, 1997
> ADD >	+	20MG/4ML	N20648 005
> ADD >			JUL 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

	AP	STERIS	5MG/ML	N70912 001
				AUG 28, 1986
		@	5MG/ML	N70912 001
				AUG 28, 1986

TABLET; ORAL

DIAZEPAM

	AB	HALSEY	2MG	N70987 001
				AUG 15, 1986

DIAZEPAM

TABLET; ORAL

DIAZEPAM

	AB	HALSEY	5MG	N70996 001
				AUG 15, 1986
	AB		10MG	N70956 001
				AUG 15, 1986
		@	2MG	N70987 001
				AUG 15, 1986
		@	5MG	N70996 001
				AUG 15, 1986
		@	10MG	N70956 001
				AUG 15, 1986

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

	AB	COPLEY PHARM	25MG	N74459 001
				JUN 25, 1997
	AB		50MG	N74459 002
				JUN 25, 1997
	AB		75MG	N74459 003
				JUN 25, 1997

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL

	AB	WEST WARD	10MG	N40204 001
				FEB 28, 1997

DIETHYLSTILBESTROL

TABLET; ORAL

DIETHYLSTILBESTROL

LILLY	1MG		N04041 004
+	5MG		N04041 005
@	1MG		N04041 004
@	5MG		N04041 005

STILBESTROL

TABLICAPS	0.5MG		N83004 001
@	0.5MG		N83004 001

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

> ADD >	AB	DANBURY PHARMA	250MG	N74400 001	
> ADD >				JUL 17, 1997	
> ADD >	AB		500MG	N74400 002	
> ADD >				JUL 17, 1997	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

AB	MYLAN	60MG	N74910 001	
			MAY 02, 1997	
AB		90MG	N74910 002	
			MAY 02, 1997	
AB		120MG	N74910 003	
			MAY 02, 1997	

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

AP	ELKINS SINN	50MG/ML	N84767 001
@		50MG/ML	N84767 001

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

AP	STERIS	10MG/ML	N83533 001
@		10MG/ML	N83533 001

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	CHELSEA LABS	50MG	N87160 001
			JUN 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC

> DLT >	+	LILLY	250MG	N50678 001
> DLT >				JUN 19, 1995
> DLT >	@		250MG	N50678 001
> ADD >				JUN 19, 1995

DOXAZOSIN MESYLATE

TABLET; ORAL
CARDURA

	PFIZER	EQ 1MG BASE	N19668 001
			NOV 02, 1990
+		EQ 8MG BASE	N19668 004
			NOV 02, 1990
+		EQ 1MG BASE	N19668 001
			NOV 02, 1990
		EQ 8MG BASE	N19668 004
			NOV 02, 1990

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL
DORYX

> DLT >	AB	PARKE DAVIS	EQ 100MG BASE	N62653 001
> DLT >				OCT 30, 1985
> ADD >	AB	WARNER CHILCOTT	EQ 100MG BASE	N62653 001
> ADD >				OCT 30, 1985

ECONAZOLE NITRATE

CREAM; TOPICAL
SPECTAZOLE

+	J AND J	1%	N18751 001
			DEC 23, 1982
+	JOHNSON RW	1%	N18751 001
			DEC 23, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN

AT	STIEFEL	2%	N64127 001
			FEB 14, 1997

ESTAZOLAM

TABLET; ORAL

> ADD >		**ESTAZOLAM**			
> ADD >	AB	TEVA	1MG	N74921 001	
> ADD >				JUL 10, 1997	
> ADD >	AB		2MG	N74921 002	
> ADD >				JUL 10, 1997	
> ADD >	AB	ZENITH GOLDLINE	1MG	N74826 001	
> ADD >				JUL 03, 1997	
> ADD >	AB		2MG	N74826 002	
> ADD >				JUL 03, 1997	
		PROSOM			
> ADD >	AB	ABBOTT	1MG	N19080 001	
> ADD >				DEC 26, 1990	
> ADD >	AB +		2MG	N19080 002	
> ADD >				DEC 26, 1990	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	ALESSE			
	+	WYETH AYERST	0.02MG;0.1MG	N20683 001
				MAR 27, 1997

TABLET; ORAL-28

ALESSE			
	WYETH AYERST	0.02MG;0.1MG	N20683 002
			MAR 27, 1997

ETODOLAC

CAPSULE; ORAL

		ETODOLAC			
> ADD >	AB	ENDO LABS	200MG	N74842 001	
> ADD >				JUL 17, 1997	
> ADD >	AB		300MG	N74842 002	
> ADD >				JUL 17, 1997	
	AB	MYLAN	200MG	N74932 001	
				MAY 16, 1997	
	AB		300MG	N74932 002	
				MAY 16, 1997	
> ADD >	AB	ZENITH GOLDLINE	200MG	N74899 001	
> ADD >				JUL 08, 1997	
> ADD >	AB		300MG	N74899 002	
> ADD >				JUL 08, 1997	

ETODOLAC

CAPSULE; ORAL

		LODINE			
	AB	WYETH AYERST	200MG	N18922 002	
				JAN 31, 1991	
	AB +		300MG	N18922 003	
				JAN 31, 1991	

TABLET; ORAL

		ETODOLAC			
	AB	ENDO LABS	400MG	N74841 001	
				JUN 27, 1997	
	AB	EON	400MG	N74903 001	
				APR 11, 1997	
> ADD >	AB	GENEVA PHARMS	400MG	N74839 001	
> ADD >				JUL 11, 1997	
	AB	INVAMED	400MG	N74846 001	
				FEB 28, 1997	
	AB	PUREPAC PHARM	400MG	N74819 001	
				FEB 28, 1997	
	AB	ROYCE LABS	400MG	N74892 001	
				APR 16, 1997	
	AB	ZENITH GOLDLINE	400MG	N74883 001	
				FEB 28, 1997	
		LODINE			
	AB	WYETH AYERST	400MG	N18922 004	
				JUL 29, 1993	

ETOPOSIDE

INJECTABLE; INJECTION

		ETOPOSIDE			
	AP	IMMUNEX	20MG/ML	N74513 001	
				MAR 14, 1996	
> ADD >	AP	PIERRE FABRE	20MG/ML	N74813 001	
> ADD >				JUL 09, 1997	
	AP	SUPERGEN	20MG/ML	N74513 001	
				MAR 14, 1996	

FLECAINIDE ACETATE

TABLET; ORAL

	TAMBOCOR			
	@ 3M		50MG	N18830 004
				AUG 23, 1988

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

@	3M	100MG	N18830 001	> ADD >	
			OCT 31, 1985	> ADD >	
@		150MG	N18830 003	> DLT >	
			JUN 03, 1988	> DLT >	
		50MG	N18830 004		
			AUG 23, 1988	> ADD >	
		100MG	N18830 001	> ADD >	
			OCT 31, 1985	> DLT >	
+		150MG	N18830 003	> DLT >	
			JUN 03, 1988		

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN

+	PFIZER	200MG/100ML	N19950 001	
			JAN 29, 1990	

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	PFIZER	200MG/100ML	N19950 003	
			SEP 29, 1992	
@		2MG/ML	N19950 005	
			JUL 08, 1994	

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+	PFIZER	200MG/100ML	N19950 001	
			JAN 29, 1990	

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	PFIZER	200MG/100ML	N19950 002	
			JAN 29, 1990	
@		2MG/ML	N19950 004	
			JUL 08, 1994	

FLUNISOLIDE

SPRAY, METERED; NASAL
NASALIDE

BX	+ DURA	0.025MG/SPRAY	N18148 001	
BX	+ SYNTEX	0.025MG/SPRAY	N18148 001	

NASAREL

BX	+ DURA	0.025MG/SPRAY	N20409 001	
			MAR 08, 1995	
BX	+ SYNTEX	0.025MG/SPRAY	N20409 001	
			MAR 08, 1995	

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCET

	@ ALPHARMA	0.025%	N88360 001	
			JAN 16, 1984	
AT	NMC	**0.025%**	**N88360 001**	
			JAN 16, 1984	

FLUOCINOLONE ACETONIDE

	@ ALPHARMA	0.01%	N88361 001	
			JAN 16, 1984	
AT	NMC	**0.01%**	**N88361 001**	
			JAN 16, 1984	

SYNALAR

AT	+ MEDICIS	**0.01%**	**N12787 004**	
AT	+	**0.025%**	**N12787 002**	
AT	+	**0.025%**	**N12787 005**	
AT	+ SYNTEX	**0.01%**	**N12787 004**	
AT	+	**0.025%**	**N12787 002**	
AT	+	**0.025%**	**N12787 005**	

SYNALAR-HP

	+ MEDICIS	0.2%	N16161 002	
	+ SYNTEX	0.2%	N16161 002	

OINTMENT; TOPICAL
SYNALAR

AT	+ MEDICIS	**0.025%**	**N13960 001**	
AT	+ SYNTEX	**0.025%**	**N13960 001**	

SOLUTION; TOPICAL
SYNALAR

AT	+ MEDICIS	**0.01%**	**N15296 001**	
AT	+ SYNTEX	**0.01%**	**N15296 001**	

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-SYNALAR

	+ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	
	+ SYNTEX	0.025%;EQ 3.5MG BASE/GM	N60700 001	

FLUOCINONIDE

CREAM; TOPICAL
LIDEX

AB	+ MEDICIS	**0.05%**	**N16908 002**	
AB	+ SYNTEX	**0.05%**	**N16908 002**	

FLUOCINONIDE

CREAM; TOPICAL

	LIDEX-E			
AB	MEDICIS	0.05%	N16908 003	
AB	SYNTEX	0.05%	N16908 003	

GEL; TOPICAL

	FLUOCINONIDE			
> ADD > AB	TARO	0.05%	N74935 001	
> ADD >			JUL 29, 1997	
	LIDEX			
AB +	MEDICIS	0.05%	N17373 001	
AB +	SYNTEX	0.05%	N17373 001	

OINTMENT; TOPICAL

	LIDEX			
AB +	MEDICIS	0.05%	N16909 002	
AB +	SYNTEX	0.05%	N16909 002	

SOLUTION; TOPICAL

	LIDEX			
AT +	MEDICIS	0.05%	N18849 001	
			APR 06, 1984	
AT +	SYNTEX	0.05%	N18849 001	
			APR 06, 1984	

FLURANDRENOLIDE

CREAM; TOPICAL

	CORDRAN SP			
> DLT > +	LILLY	0.025%	N12806 003	
> DLT > +		0.05%	N12806 002	
> ADD > +	OCLASSEN	0.025%	N12806 003	
> ADD > +		0.05%	N12806 002	

LOTION; TOPICAL

	CORDRAN			
> DLT > AT +	LILLY	0.05%	N13790 001	
> ADD > AT +	OCLASSEN	0.05%	N13790 001	

OINTMENT; TOPICAL

	CORDRAN			
> DLT > +	LILLY	0.025%	N12806 004	
> DLT > +		0.05%	N12806 001	
> ADD > +	OCLASSEN	0.025%	N12806 004	
> ADD > +		0.05%	N12806 001	

FLURANDRENOLIDE

TAPE; TOPICAL

	CORDRAN			
> DLT > +	LILLY	0.004MG/SQ CM	N16455 001	
> ADD > +	OCLASSEN	0.004MG/SQ CM	N16455 001	

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

	FLURAZEPAM HCL			
AB	HALSEY	15MG	N71808 001	
			JAN 07, 1988	
AB		30MG	N71809 001	
			JAN 07, 1988	
@		15MG	N71808 001	
			JAN 07, 1988	
@		30MG	N71809 001	
			JAN 07, 1988	

FLURBIPROFEN

TABLET; ORAL

	FLURBIPROFEN			
AB	SIDMAK LABS NJ	50MG	N74647 001	
			APR 01, 1997	
AB		100MG	N74647 002	
			APR 01, 1997	
AB	WARNER CHILCOTT	100MG	N74560 002	
			MAY 16, 1997	

FOLIC ACID

TABLET; ORAL

	FOLIC ACID			
AA	DANBURY PHARMA	1MG	N80680 001	
AA +		1MG	N80680 001	
	FOLVITE			
AA +	LEDERLE	1MG	N05897 004	
@		1MG	N05897 004	

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	SIDMAK LABS NJ	5MG	N74619 001	APR 04, 1997
AB		10MG	N74619 002	APR 04, 1997

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE

AA	HALSEY	500MG	N89459 001	OCT 10, 1986
	@	500MG	N89459 001	OCT 10, 1986

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL
GRIFULVIN V

	+ J AND J	125MG/5ML	N50448 001	
		125MG/5ML	N62483 001	JAN 26, 1984
	+ JOHNSON RW	125MG/5ML	N50448 001	
		125MG/5ML	N62483 001	JAN 26, 1984

TABLET; ORAL
GRIFULVIN V

AB	J AND J	250MG	N60618 002	
AB		250MG	N62279 002	
AB		500MG	N60618 003	
AB		500MG	N62279 003	
		125MG	N60618 001	
		125MG	N62279 001	
AB	JOHNSON RW	250MG	N60618 002	
AB		250MG	N62279 002	
AB		500MG	N60618 003	
AB		500MG	N62279 003	
		125MG	N60618 001	
		125MG	N62279 001	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL

AB	AMIDE PHARM	EQ 1MG BASE	N74673 001	FEB 28, 1997
AB		EQ 2MG BASE	N74673 002	FEB 28, 1997
AB	MYLAN	EQ 1MG BASE	N74796 001	JAN 27, 1997
AB		EQ 2MG BASE	N74796 002	JAN 27, 1997
AB	ROYCE LABS	EQ 1MG BASE	N74762 001	JUN 25, 1997
AB		EQ 2MG BASE	N74762 002	JUN 25, 1997

HALCINONIDE

CREAM; TOPICAL
HALOG

>DLT>	WESTWOOD SQUIBB	0.025%	N17818 001	
>ADD>	@	0.025%	N17818 001	

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALDOL

	+ JOHNSON RW	EQ 50MG BASE/ML	N18701 001	JAN 14, 1986
	+	EQ 100MG BASE/ML	N18701 002	JAN 31, 1997

HALDOL DECANOATE 100

	+ JOHNSON RW	EQ 100MG BASE/ML	N18701 002	OCT 31, 1989

HALDOL DECANOATE 50

	+ JOHNSON RW	EQ 50MG BASE/ML	N18701 001	JAN 14, 1986

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP FLUSH KIT IN PLASTIC CONTAINER

AP	FUJISAWA	10 UNITS/ML	N17029 017	DEC 05, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER

AP	**FUJISAWA**	**100 UNITS/ML**	**N17029 018 DEC 05, 1985**
@		10 UNITS/ML	N17029 017 DEC 05, 1985
@		100 UNITS/ML	N17029 018 DEC 05, 1985

HEPARIN SODIUM

AP	FUJISAWA	**20,000 UNITS/ML**	**N17029 004**
AP	STERIS	**1,000 UNITS/ML**	**N17064 002**
@		1,000 UNITS/ML	N17064 002

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROPANE

AA	**HALSEY**	**1.5MG/5ML;5MG/5ML**	**N88066 001 JUN 28, 1985**
@		1.5MG/5ML;5MG/5ML	N88066 001 JUN 28, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HCL

AP	**LUITPOLD**	**20MG/ML**	**N40136 001 JUN 30, 1997**

TABLET; ORAL

HYDRALAZINE HCL

AA	**HALSEY**	**25MG**	**N89130 001 JAN 15, 1986**
AA		**100MG**	**N89178 001 JAN 15, 1986**
@		25MG	N89130 001 JAN 15, 1986
@		100MG	N89178 001 JAN 15, 1986

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIRETIC

	SCHWARZ PHARMA	12.5MG;7.5MG	N20729 001 JUN 27, 1997
+		25MG;15MG	N20729 002 JUN 27, 1997

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	GENEVA PHARMS	**25MG;37.5MG**	**N74821 001 JUN 05, 1997**

HYDROCORTISONE

CREAM; TOPICAL

DERMACORT

AT	MONARCH PHARMS	**1%**	**N83011 002**
AT	SOLVAY	**1%**	**N83011 002**

HYDROCORTISONE

> ADD >	@ ALPHARMA	2.5%	N89754 001 FEB 01, 1989
> DLT >	**AT NMC**	**2.5%**	**N89754 001 FEB 01, 1989**

PROCTOCORT

AT	MONARCH PHARMS	**1%**	**N83011 001**
AT	SOLVAY	**1%**	**N83011 001**

SYNACORT

AT	MEDICIS	**1%**	**N87458 001**
AT		**2.5%**	**N87457 001**
@		0.5%	N87459 001
AT	SYNTEX	**1%**	**N87458 001**
AT		**2.5%**	**N87457 001**
@		0.5%	N87459 001

TABLET; ORAL

HYDROCORTISONE

BP	**PUREPAC PHARM**	**10MG**	**N84247 003 AUG 31, 1982**
BP		**20MG**	**N84247 002**
@		10MG	N84247 003 AUG 31, 1982
@		20MG	N84247 002

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		CORTISPORIN				
AT	+	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML			N50479 001
AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML			N50479 001
		OTOCORT				
AT		STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	> DLT >		N60730 002
	@		1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	> ADD >		N60730 002

SUSPENSION/DROPS; OTIC

		OTOCORT				
AT		STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	> DLT >		N62521 001 JUL 11, 1985
	@		1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	> ADD >		N62521 001 JUL 11, 1985
		PEDIOTIC				
AT		GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML			N62822 001 SEP 29, 1987
AT		MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML			N62822 001 SEP 29, 1987

HYDROCORTISONE; UREA

CREAM; TOPICAL

		ALPHADERM				
	@	BIOGLAN	1%;10%			N86008 001
	@	VIVAN	1%;10%			N86008 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

		HEMSOL-HC				
AT		ABLE	1%			N81274 001 JUN 19, 1992
	+		1%			N81274 001 JUN 19, 1992
		HYDROCORTISONE ACETATE				
AT	+	PUREPAC PHARM	1%			N86052 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

		HYDROCORTISONE ACETATE				
	@	PUREPAC PHARM	1%			N86052 001

INJECTABLE; INJECTION

		HYDROCORTISONE ACETATE				
BP		AKORN	25MG/ML	> DLT >		N09637 001
BP			50MG/ML	> DLT >		N09637 002
	@		25MG/ML	> ADD >		N09637 001
	@		50MG/ML	> ADD >		N09637 002
BP		STERIS	25MG/ML			N83759 001
BP			50MG/ML			N83759 002
	@		25MG/ML			N83759 001
	@		50MG/ML			N83759 002
		HYDROCORTONE				
BP	+	MERCK SHARP DOHME	50MG/ML	> DLT >		N08228 004
	+		50MG/ML	> ADD >		N08228 004

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

		CORTISPORIN				
	+	GLAXO WELLCOME	0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM			N50218 001 AUG 09, 1985
	+	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM			N50218 001 AUG 09, 1985

HYDROCORTISONE BUTEPRATE

CREAM; TOPICAL

		PANDEL				
	+	SAVAGE LABS	0.1%			N20453 001 FEB 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

		HYDROCORTISONE SODIUM SUCCINATE				
AP		ELKINS SINN	EQ 1GM BASE/VIAL			N87569 001
	@		EQ 1GM BASE/VIAL			N87569 001

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HCL

AP	SANOFI	10MG/ML	N74598 001 JUN 19, 1997

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

AB	HALSEY	25MG	N89117 001 MAY 02, 1988
@		25MG	N89117 001 MAY 02, 1988
AB	KV PHARM	10MG	N87819 001 JUN 23, 1982
AB		25MG	N87820 001 JUN 23, 1982
AB		50MG	N87821 001 JUN 23, 1982
AB		100MG	N87822 001 JUN 23, 1982
@		10MG	N87819 001 JUN 23, 1982
@		25MG	N87820 001 JUN 23, 1982
@		50MG	N87821 001 JUN 23, 1982
@		100MG	N87822 001 JUN 23, 1982

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HY-PAM

AB	EON	EQ 25MG HCL	N87479 001

HYDROXYZINE PAMOATE

AB	EON	EQ 25MG HCL	N87479 001

IBUPROFEN

SUSPENSION; ORAL
IBU

BX	KNOLL PHARM	100MG/5ML	N19784 001 DEC 18, 1989

IBUPROFEN

SUSPENSION; ORAL
IBU

@	KNOLL PHARM	100MG/5ML	N19784 001 DEC 18, 1989

TABLET; ORAL
IBUPROFEN

AB	PUREPAC PHARM	800MG	N71964 001 FEB 01, 1988
@		800MG	N71964 001 FEB 01, 1988

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN PFS

+	PHARMACIA AND UPJOHN	1MG/ML	N50734 001 FEB 17, 1997

IFOSFAMIDE

INJECTABLE; INJECTION
IFEX

+	BRISTOL MYERS SQUIBB	1GM/VIAL	N19763 001 DEC 30, 1988
+		3GM/VIAL	N19763 002 DEC 30, 1988
@		1GM/VIAL	N19763 001 DEC 30, 1988
@		3GM/VIAL	N19763 002 DEC 30, 1988

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION
IFEX/MESNEX KIT

+	BRISTOL MYERS SQUIBB	1GM/VIAL;100MG/ML	N19763 003 OCT 10, 1992
+		3GM/VIAL;100MG/ML	N19763 004 OCT 10, 1992

IMIQUIMOD

CREAM; TOPICAL

	ALDARA			
+	3M	5%	N20723 001	FEB 27, 1997

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	MYLAN	1.25MG	N74461 002	MAR 26, 1997
AB	NOVOPHARM	1.25MG	N74665 001	APR 04, 1997
AB		2.5MG	N74665 002	APR 04, 1997

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

	INDIUM IN-111 OXYQUINOLINE			
	AMERSHAM	1mCi/ML	N19044 001	DEC 23, 1985
	MEDI PHYSICS	1mCi/ML	N19044 001	DEC 23, 1985

INDOCYANINE GREEN

INJECTABLE; INJECTION

	CARDIO-GREEN				
+	AKORN	25MG/VIAL	N11525 001	>ADD>	
+		50MG/VIAL	N11525 002	>ADD>	
+	BECTON DICKINSON	25MG/VIAL	N11525 001	>DLT>	
+		50MG/VIAL	N11525 002	>DLT>	
				>ADD>	
				>ADD>	

IOPAMIDOL

INJECTABLE; INJECTION

	IOPAMIDOL-250			
AP	FUJISAWA	51%	N74679 001	APR 02, 1997
	IOPAMIDOL-300			
AP	ABBOTT	61%	N74638 001	APR 30, 1997

IOPAMIDOL

INJECTABLE; INJECTION

	IOPAMIDOL-300			
AP	FUJISAWA	61%	N74679 002	APR 02, 1997
	IOPAMIDOL-300 IN PLASTIC CONTAINER			
AP	ABBOTT	61%	N74637 001	APR 03, 1997
	IOPAMIDOL-370			
AP	FUJISAWA	76%	N74679 003	APR 02, 1997
	ISOVUE-250			
AP	+ BRACCO	51%	N18735 007	JUL 06, 1992
AP	+	51%	N20327 002	OCT 12, 1994

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

	ATROVENT			
AN	+ BOEHRINGER INGELHEIM	0.02%	N20228 001	SEP 29, 1993
	IPRATROPIUM BROMIDE			
AN	DEY	0.02%	N74755 001	JAN 10, 1997

ISONIAZID

SYRUP; ORAL

	ISONIAZID			
AA	+ CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983
	+	50MG/5ML	N88235 001	NOV 10, 1983
AA	MIKART	50MG/5ML	N81118 001	JUL 21, 1997
	LANIAZID			
AA	LANNETT	50MG/5ML	N89243 001	FEB 03, 1986
	@	50MG/5ML	N89243 001	FEB 03, 1986

TABLET; ORAL

	ISONIAZID			
AA	MIKART	100MG	N40090 001	JUN 26, 1997

ISONIAZID

TABLET; ORAL
ISONIAZID

AA	MIKART	300MG	N40090 002 JUN 26, 1997	

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
ISOPROTERENOL HCL

BN	+ 3M	0.12MG/INH	N10375 004	
	+	0.12MG/INH	N10375 004	
BN	ALPHARMA	0.12MG/INH	N85904 001	
	@	0.12MG/INH	N85904 001	

INJECTABLE; INJECTION
ISUPREL

AP	+ ABBOTT	0.2MG/ML	N10515 001	
AP	+ SANOFI WINTHROP	0.2MG/ML	N10515 001	

ITRACONAZOLE

SOLUTION; ORAL
SPORANOX

	+ JANSSEN	10MG/ML	N20657 001 FEB 21, 1997	

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	ABBOTT	15MG/ML	N74801 001 JUN 05, 1997	
AP		15MG/ML	N74802 001 JUN 05, 1997	
AP		30MG/ML	N74801 002 JUN 05, 1997	
AP		30MG/ML	N74802 002 JUN 05, 1997	

TABLET; ORAL
KETOROLAC TROMETHAMINE

AB	MYLAN	10MG	N74761 001 MAY 16, 1997	

> ADD >

> ADD >
> ADD >
> ADD >
> ADD >

KETOROLAC TROMETHAMINE

TABLET; ORAL
KETOROLAC TROMETHAMINE

AB	ROXANE	10MG	N74790 001 JUN 26, 1997	
AB	TEVA	10MG	N74754 001 MAY 16, 1997	

TORADOL

AB	+ SYNTEX	10MG	N19645 001 DEC 20, 1991	

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL
PREVACID

	TAP HOLDINGS	15MG	N20406 001 MAY 10, 1995	
	+	30MG	N20406 002 MAY 10, 1995	

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

	TAP HOLDINGS	15MG	N20406 001 MAY 10, 1995	
	+	30MG	N20406 002 MAY 10, 1995	

LETROZOLE

TABLET; ORAL
FEMARA

	+ NOVARTIS	2.5MG	N20726 001 JUL 25, 1997	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	+ ABBOTT	EQ 10MG BASE/ML	N40147 001 JUN 25, 1997	
AP	+ BEDFORD	EQ 200MG BASE/VIAL	N40056 001 MAY 23, 1995	
	+	EQ 200MG BASE/VIAL	N40056 001 MAY 23, 1995	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP		GENSIA	EQ 350MG BASE/VIAL	N40174 001 JUN 12, 1997
AP	+	IMMUNEX	EQ 350MG BASE/VIAL	N08107 005 APR 05, 1989
AP		PHARMACHEMIE	EQ 50MG BASE/VIAL	N89628 001 APR 17, 1997
AP			EQ 100MG BASE/VIAL	N89915 001 APR 17, 1997

TABLET; ORAL
LEUCOVORIN CALCIUM

AB		PHARMACHEMIE	EQ 5MG BASE	N73099 001 MAR 28, 1997
AB			EQ 25MG BASE	N73101 001 MAR 28, 1997

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT-3

	+	TAP HOLDINGS	11.25MG/VIAL	N20708 001 MAR 07, 1997

LUPRON DEPOT-4

	+	TAP HOLDINGS	30MG/VIAL	N20517 002 MAY 30, 1997

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHOBID

		SOLVAY	300MG	N18027 001
	+		300MG	N18027 001

LORAZEPAM

SOLUTION; ORAL
LORAZEPAM

	+	ROXANE	0.5MG/5ML	N74648 001 MAR 18, 1997

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE

		FUJISAWA	500MG/ML	N19316 001 SEP 08, 1986
	+		500MG/ML	N19316 001 SEP 08, 1986

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

		ABBOTT	1GM/100ML	N20488 001 JUL 11, 1995
	+		1GM/100ML	N20488 001 JUL 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER

		ABBOTT	4GM/100ML	N20309 001 JUN 24, 1994
			80MG/ML	N20309 002 JUN 24, 1994
	+		4GM/100ML	N20309 001 JUN 24, 1994
	+		80MG/ML	N20309 002 JUN 24, 1994

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL

AA		KV PHARM	12.5MG	N85524 001
AA			25MG	N85523 001
	@		12.5MG	N85524 001
	@		25MG	N85523 001
AA		VINTAGE PHARMS	12.5MG	N40179 001 JAN 30, 1997
AA			25MG	N40179 002 JAN 30, 1997

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
HUMEGON

AB	+	ORGANON	75 IU/VIAL;75 IU/VIAL	N20328 001 SEP 01, 1994
AB			75 IU/VIAL;75 IU/VIAL	N20328 001 SEP 01, 1994
AB	+		150 IU/VIAL;150 IU/VIAL	N20328 002 SEP 01, 1994

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	HUMEGON			
AB	ORGANON	150 IU/VIAL;150 IU/VIAL	N20328 002	SEP 01, 1994
	REPRONAL			
AB	FERRING	75 IU/VIAL;75 IU/VIAL	N73598 001	JAN 30, 1997
AB		75 IU/VIAL;75 IU/VIAL	N73598 001	JAN 30, 1997
AB		150 IU/VIAL;150 IU/VIAL	N73599 001	JAN 30, 1997
AB		150 IU/VIAL;150 IU/VIAL	N73599 001	JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MEPERIDINE HCL			
AP	MALLINCKRODT	10MG/ML	N40163 001	MAY 12, 1997

TABLET; ORAL

	MEPERIDINE HCL			
AA	ROXANE	50MG	N40110 001	MAR 12, 1997
AA		100MG	N40110 002	MAR 12, 1997
AA	ROYCE LABS	50MG	N40186 001	JUN 30, 1997
AA		100MG	N40186 002	JUN 30, 1997

MEPROBAMATE

TABLET; ORAL

		MEPROBAMATE			
>DLT<	AA	PUREPAC PHARM	200MG	N84804 001	
>DLT<	AA		400MG	N84804 002	
>ADD<	@		200MG	N84804 001	>ADD<
>ADD<	@		400MG	N84804 002	>ADD<
					>ADD<
					>ADD<

METAPROTERENOL SULFATE

SYRUP; ORAL

	METAPROTERENOL SULFATE			
AA	JVL	10MG/5ML	N74702 001	MAR 24, 1997
AA	MORTON GROVE	10MG/5ML	N71656 001	OCT 13, 1987
AA		10MG/5ML	N74702 001	MAR 24, 1997
	@	10MG/5ML	N71656 001	OCT 13, 1987

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE			
	BRISTOL MYERS SQUIBB	500MG	N20357 001	DEC 29, 1994
	+	850MG	N20357 002	DEC 29, 1994
		500MG	N20357 001	MAR 03, 1995
	+	850MG	N20357 002	MAR 03, 1995

METHACHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; INHALATION

	PROVOCHOLINE		
	METHAPHARM	100MG/VIAL	N19193 001 OCT 31, 1986
	ROCHE	100MG/VIAL	N19193 001 OCT 31, 1986

METHAZOLAMIDE

TABLET; ORAL

	METHAZOLAMIDE			
AB	APPLIED ANAL	25MG	N40011 001	JUL 17, 1997
AB		50MG	N40011 002	JUL 17, 1997

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

AA	PUREPAC PHARM	**500MG**	**N85718 001**
AA		**750MG**	**N85718 002**
@		500MG	N85718 001
@		750MG	N85718 002

METHOTREXATE SODIUM

INJECTABLE; INJECTION
MEXATE-AQ PRESERVED

AP	BRISTOL MYERS	**EQ 25MG BASE/ML**	**N89887 001**
@	BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	N89887 001

APR 14, 1989
APR 14, 1989

METHOXSALEN

CAPSULE; ORAL
OXSORALEN-ULTRA

+	ICN	10MG	N19600 001

OCT 30, 1986

CAPSULE, LIQUID FILLED; ORAL
OXSORALEN-ULTRA

+	ICN	10MG	**N19600 001**

OCT 30, 1986

METHYLDOPA

TABLET; ORAL
METHYLDOPA

AB	HALSEY	**125MG**	**N71751 001**
AB		**250MG**	**N71752 001**
@		125MG	N71751 001
@		250MG	N71752 001
AB	PUREPAC PHARM	**125MG**	**N70749 001**
AB		**250MG**	**N70750 001**

MAR 28, 1988
MAR 28, 1988
FEB 07, 1986
FEB 07, 1986

METHYLDOPA

TABLET; ORAL
METHYLDOPA

AB	PUREPAC PHARM	**500MG**	**N70452 001**
@		125MG	N70749 001
@		250MG	N70750 001
@		500MG	N70452 001

FEB 07, 1986
FEB 07, 1986
FEB 07, 1986
FEB 07, 1986

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	FAULDING	**EQ 5MG BASE/ML**	**N71990 001**
@		EQ 5MG BASE/ML	N71990 001

JAN 18, 1989
JAN 18, 1989

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	MUTUAL PHARM	**EQ 5MG BASE**	**N71536 002**

JAN 16, 1997

METOLAZONE

TABLET; ORAL
MYKROX

	MEDEVA	0.5MG	N19532 001
+		0.5MG	N19532 001

OCT 30, 1987
OCT 30, 1987

METRONIDAZOLE

GEL; VAGINAL
METROGEL-VAGINAL

+	3M	0.75%	N20208 001
+	CURATEK	0.75%	N20208 001

AUG 17, 1992
AUG 17, 1992

METRONIDAZOLE

INJECTABLE; INJECTION
METRONIDAZOLE

AP	STERIS	500MG/100ML	N70042 001 DEC 20, 1984
	@	500MG/100ML	N70042 001 DEC 20, 1984

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	WATSON LABS	150MG	N74711 001 FEB 26, 1997
AB		200MG	N74711 002 FEB 26, 1997
AB		250MG	N74711 003 FEB 26, 1997

MIBEFRADIL DIHYDROCHLORIDE

TABLET; ORAL
POSICOR

	ROCHE	EQ 50MG BASE	N20689 001 JUN 20, 1997
	+	EQ 100MG BASE	N20689 002 JUN 20, 1997

MICONAZOLE

>_DLT_>	INJECTABLE; INJECTION			
>_DLT_>	MONISTAT			
>_DLT_>	+ JANSSEN	10MG/ML	N18040 001	
>_ADD_>	@	10MG/ML	N18040 001	

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM

	+ J AND J	2%	N17494 001
	+ JOHNSON RW	2%	N17494 001

LOTION; TOPICAL
MONISTAT-DERM

	@ J AND J	2%	N17739 001

MICONAZOLE NITRATE

LOTION; TOPICAL
MONISTAT-DERM

	@ JOHNSON RW	2%	N17739 001

MIRTAZAPINE

TABLET; ORAL
REMERON

	+ ORGANON	30MG	N20415 002 JUN 14, 1996
		30MG	N20415 002 JUN 14, 1996
	+	45MG	N20415 003 MAR 17, 1997

MYCOPHENOLATE MOFETIL

TABLET; ORAL
CELLCEPT

	+ SYNTEX	500MG	N50723 001 JUN 19, 1997

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB	ROYCE LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997

TALWIN NX

AB	+ SANOFI	EQ 0.5MG BASE; EQ 50MG BASE	N18733 001 DEC 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AO	STERIS	50MG/ML	N87598 001 OCT 06, 1983
AO		100MG/ML	N87599 001 OCT 06, 1983

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

@	STERIS	50MG/ML	N87598 001	
			OCT 06, 1983	
@		100MG/ML	N87599 001	
			OCT 06, 1983	

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION
TILADE

+	FISONS	1.75MG/INH	N19660 001	> DLT >
			DEC 30, 1992	> ADD >
+	RHONE POULENC RORER	1.75MG/INH	N19660 001	
			DEC 30, 1992	

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE

@	BRISTOL MYERS SQUIBB	50MG	N20152 001	> DLT >
			DEC 22, 1994	> DLT >
+		50MG	N20152 001	> ADD >
			DEC 22, 1994	> ADD >

NELFINAVIR MESYLATE

POWDER FOR RECONSTITUTION; ORAL
VIRACEPT

+	AGOURON	EQ 50MG BASE/SCOOPFUL	N20778 001
			MAR 14, 1997

TABLET; ORAL
VIRACEPT

+	AGOURON	EQ 250MG BASE	N20779 001
			MAR 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX

AA	PHARMA TEK	100%	N61579 001	
		100%	N61579 001	

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEOMYCIN SULFATE

AA	PADDOCK	100%	N62385 001	
			JUN 01, 1982	

NIACIN

TABLET; ORAL
NIACIN

AA	HALSEY	500MG	N83453 001	
@		500MG	N83453 001	
AA	PUREPAC PHARM	500MG	N83271 001	
@		500MG	N83271 001	

TABLET, EXTENDED RELEASE; ORAL
NIASPAN

+	KOS	375MG	N20381 001	> ADD >
			JUL 28, 1997	> ADD >
+		500MG	N20381 002	> ADD >
			JUL 28, 1997	> ADD >
+		750MG	N20381 003	> ADD >
			JUL 28, 1997	> ADD >
+		1GM	N20381 004	> ADD >
			JUL 28, 1997	> ADD >

NIASPAN TITRATION STARTER PACK

+	KOS	375MG;500MG;750MG	N20381 005	> ADD >
			JUL 28, 1997	> ADD >

NICOTINE

INHALANT; INHALATION
NICOTROL

+	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N20714 001
			MAY 02, 1997

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTION

AB	MYLAN	100MG	N74967 002	> ADD >
			JUL 09, 1997	> ADD >

NITROFURANTOIN

AB	MYLAN	50MG	N74967 001	> ADD >
			JUL 09, 1997	> ADD >

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
LEVOPHED

+	ABBOTT	EQ 1MG BASE/ML	N07513 001
+	SANOFI WINTHROP	EQ 1MG BASE/ML	N07513 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	INVAMED	**EQ 10MG BASE**	**N74835 001** JUN 30, 1997
AB		**EQ 25MG BASE**	**N74835 002** JUN 30, 1997
AB		**EQ 50MG BASE**	**N74835 003** JUN 30, 1997
AB		**EQ 75MG BASE**	**N74835 004** JUN 30, 1997

NYSTATIN

CREAM; TOPICAL
MYKINAC

> ADD >	@ ALPHARMA	100,000 UNITS/GM	N62387 001 JUL 29, 1982	
> ADD >				
> DLT > **AT**	NMC	**100,000 UNITS/GM**	**N62387 001 JUL 29, 1982**	
> DLT >				

OINTMENT; TOPICAL
MYKINAC

> ADD >	@ ALPHARMA	100,000 UNITS/GM	N62731 001 SEP 22, 1986	
> ADD >				
> DLT > **AT**	NMC	**100,000 UNITS/GM**	**N62731 001 SEP 22, 1986**	
> DLT >				

SUSPENSION; ORAL
NYSTATIN

> DLT > **AA**	ALPHARMA	**100,000 UNITS/ML**	**N62571 001 OCT 29, 1985**	
> DLT >				
> ADD >	@	100,000 UNITS/ML	N62571 001 OCT 29, 1985	
> ADD >				

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL
ZOFRAN

+	GLAXO WELLCOME	EQ 4MG BASE/5ML	N20605 001 JAN 24, 1997

OXACILLIN SODIUM

CAPSULE; ORAL
BACTOCILL

AB	SMITHKLINE BEECHAM	**EQ 250MG BASE**	**N61336 001**
AB +		**EQ 250MG BASE**	**N61336 001**
	OXACILLIN SODIUM		
AB	APOTHECON	**EQ 250MG BASE**	**N61450 002**
AB +		**EQ 500MG BASE**	**N61450 001**
@		EQ 250MG BASE	N61450 002
@		EQ 500MG BASE	N61450 001

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
CHOLEDYL SA

> DLT > +	PARKE DAVIS	600MG	N86742 001
> ADD > +	WARNER CHILCOTT	600MG	N86742 001

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE

AA	MORTON GROVE	**5MG/5ML**	**N74868 001** FEB 12, 1997

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

+	PURDUE FREDERICK	10MG	N20553 001 DEC 12, 1995
+		20MG	N20553 002 DEC 12, 1995
+		40MG	N20553 003 DEC 12, 1995
+	PURDUE PHARMA	10MG	N20553 001 DEC 12, 1995

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	OXYCONTIN				
	+ PURDUE PHARMA	20MG	N20553 002		
			DEC 12, 1995		
	+	40MG	N20553 003		
			DEC 12, 1995		
	+	80MG	N20553 004		
			JAN 06, 1997		

OXYMETHOLONE

TABLET; ORAL

	ANADROL-50		
>DLT>	+ SYNTEX	50MG	N16848 001
>ADD>	+ UNIMED	50MG	N16848 001

OXYTOCIN

SOLUTION; NASAL

	SYNTOCINON		
	+ NOVARTIS	40 USP UNITS/ML	N12285 001
	@	40 USP UNITS/ML	N12285 001

PAROMOMYCIN SULFATE

CAPSULE; ORAL

	HUMATIN		
AB	+ PARKE DAVIS	**EQ 250MG BASE**	**N60521 001**
AB		**EQ 250MG BASE**	**N62310 001**
	PAROMOMYCIN SULFATE		
AB	CARACO	**EQ 250MG BASE**	**N64171 001** JUN 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

	PAXIL		
	+ SMITHKLINE BEECHAM	EQ 10MG BASE/5ML	N20710 001 JUN 25, 1997

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

		PENTOXIFYLLINE		
>ADD>	**AB**	ESI LEDERLE	**400MG**	**N74877 001** JUL 08, 1997
>ADD>	**AB**	MYLAN	**400MG**	**N74425 001** JUL 08, 1997
>ADD>	**AB**	PUREPAC PHARM	**400MG**	**N74878 001** JUL 09, 1997
		TRENTAL		
>ADD>	**AB**	+ HOECHST MARION RSSL	**400MG**	**N18631 001** AUG 30, 1984

PERINDOPRIL ERBUMINE

TABLET; ORAL

	ACEON		
	RHONE POULENC RORER	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
	+	8MG	N20184 003 DEC 30, 1993
	@	2MG	N20184 001 DEC 30, 1993
	@	4MG	N20184 002 DEC 30, 1993
	@	8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	PHENDIMETRAZINE TARTRATE		
BC	GRAHAM DM	105MG	N87214 001 MAY 26, 1982
BC		105MG	N88020 001 AUG 16, 1982
BC		105MG	N88028 001 AUG 16, 1982
BC		105MG	N88062 001 SEP 13, 1982
BC		105MG	N88063 001 SEP 10, 1982
BC		105MG	N88111 001 OCT 18, 1982

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

@	GRAHAM DM	105MG	N87214 001 MAY 26, 1982
@		105MG	N88020 001 AUG 16, 1982
@		105MG	N88028 001 AUG 16, 1982
@		105MG	N88062 001 SEP 13, 1982
@		105MG	N88063 001 SEP 10, 1982
@		105MG	N88111 001 OCT 18, 1982

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	INWOOD LABS	**35MG**	**N84740 001**
AA		**35MG**	**N84741 001**
AA		**35MG**	**N84742 001**
AA		**35MG**	**N84743 001**
@		35MG	N84740 001
@		35MG	N84741 001
@		35MG	N84742 001
@		35MG	N84743 001
> DLT > **AA**	KV PHARM	**35MG**	**N85525 001**
> ADD > @		35MG	N85525 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	AMIDE PHARM	**30MG**	**N40227 001** JUN 18, 1997
AA		**37.5MG**	**N40228 001** JUN 19, 1997
AA	KING PHARMS	**30MG**	**N40083 001** MAR 07, 1997

TABLET; ORAL
PHENTERMINE HCL

AA	AMIDE PHARM	**37.5MG**	**N40190 001** MAY 30, 1997

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN

	PARKE DAVIS	30MG	N84349 001
+		30MG	N84349 001

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	LEMMON	**5MG**	**N74123 001** APR 17, 1997
AB		**10MG**	**N74123 002** APR 17, 1997
AB	TEVA	**5MG**	**N74123 001** APR 17, 1997
AB		**10MG**	**N74123 002** APR 17, 1997

PIROXICAM

CAPSULE; ORAL
PIROXICAM

> ADD > **AB**	EGIS	**10MG**	**N74808 001** JUL 08, 1997
> ADD > **AB**		**20MG**	**N74808 002** JUL 08, 1997

PODOFILOX

GEL; TOPICAL
CONDYLOX

+	OCLASSEN	0.5%	N20529 001 MAR 13, 1997

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
POLYTRIM

AT +	ALLERGAN	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N50567 001** OCT 20, 1988

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	BAUSCH AND LOMB	10,000 UNITS/ML; EQ 1MG BASE/ML	N64120 001	FEB 14, 1997

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	+ ABBOTT	745MG/100ML	N20161 001	NOV 30, 1992
AP	+	14.9MG/ML	N20161 005	NOV 30, 1992
	@	745MG/100ML	N20161 001	NOV 30, 1992
	@	14.9MG/ML	N20161 005	NOV 30, 1992
AP	+ BAXTER HLTHCARE	746MG/100ML	N19904 005	DEC 17, 1990
AP	+	14.9MG/ML	N19904 001	DEC 26, 1989
	+	746MG/100ML	N19904 005	DEC 17, 1990
	+	14.9MG/ML	N19904 001	DEC 26, 1989

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+ ABBOTT	1.49GM/100ML	N20161 002	NOV 30, 1992
	@	1.49GM/100ML	N20161 002	NOV 30, 1992
AP	+ BAXTER HLTHCARE	1.49GM/100ML	N19904 006	DEC 17, 1990
	+	1.49GM/100ML	N19904 006	DEC 17, 1990

> ADD > PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE

> ADD > TABLET; ORAL
> ADD > MIRAPEX

> ADD >	+ PHARMACIA AND UPJOHN	0.125MG	N20667 001	JUL 01, 1997
> ADD >		0.25MG	N20667 002	JUL 01, 1997

> ADD > PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE

> ADD > TABLET; ORAL
> ADD > MIRAPEX

> ADD >	PHARMACIA AND UPJOHN	1MG	N20667 003	JUL 01, 1997
> ADD >	@	1.25MG	N20667 004	JUL 01, 1997
> ADD >	+	1.5MG	N20667 005	JUL 01, 1997

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

BX	PUREPAC PHARM	5MG	N80325 001	
	@	5MG	N80325 001	

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

	STERIS	25MG/ML	N83654 001	
	@	25MG/ML	N83654 001	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PEDIAPRED

+	PISONS	EQ 5MG BASE/5ML	N19157 001	MAY 28, 1986
+	MEDEVA	EQ 5MG BASE/5ML	N19157 001	MAY 28, 1986

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	HALSEY	5MG	N80300 001	
	@	5MG	N80300 001	

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL

AB	INWOOD LABS	500MG	N89840 001 MAR 06, 1989
@		500MG	N89840 001 MAR 06, 1989

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINE HCL

AP	STERIS	1%	N83535 001
AP		2%	N83535 002
@		1%	N83535 001
@		2%	N83535 002

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	STERIS	EQ 5MG BASE/ML	N89605 001 JUL 08, 1987
@		EQ 5MG BASE/ML	N89605 001 JUL 08, 1987

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	DURAMED	EQ 5MG BASE	N40207 001 MAY 01, 1997
AB		EQ 10MG BASE	N40207 002 MAY 01, 1997

PROGESTERONE

GEL; VAGINAL
CRINONE

>ADD>	COLUMBIA RES LABS	4%	N20701 001 JUL 31, 1997
>ADD> +		8%	N20701 002 JUL 31, 1997

PROGESTERONE

GEL; VAGINAL
CRINONE

+	COLUMBIA RES LABS	8%	N20756 001 MAY 13, 1997

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	STERIS	25MG/ML	N83532 001
AP		50MG/ML	N83532 002
@		25MG/ML	N83532 001
@		50MG/ML	N83532 002

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

BP	PAR PHARM	15MG	N88377 001 DEC 08, 1983
@		15MG	N88377 001 DEC 08, 1983

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

>DLT> AA	ROXANE	32MG	N83089 001
>DLT> AA		65MG	N83089 002
>ADD> @		32MG	N83089 001
>ADD> @		65MG	N83089 002

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

>DLT> AB	ROXANE	10MG	N70516 001 JUL 07, 1986
>DLT> AB		20MG	N70517 001 JUL 07, 1986
>DLT> AB		40MG	N70518 001 JUL 07, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

> DLT >	AB	ROXANE	60MG	N70519 001	
> DLT				SEP 24, 1986	
> DLT >	AB		80MG	N70520 001	
> DLT >				JUL 07, 1986	
> DLT >	AB		90MG	N70521 001	
> DLT >				SEP 24, 1986	
> ADD >		@	10MG	N70516 001	
> ADD >				JUL 07, 1986	
> ADD >		@	20MG	N70517 001	
> ADD >				JUL 07, 1986	
		@	40MG	N70518 001	
				JUL 07, 1986	
> ADD >		@	60MG	N70519 001	
> ADD >				SEP 24, 1986	
> ADD >		@	80MG	N70520 001	
> ADD >				JUL 07, 1986	
> ADD >		@	90MG	N70521 001	
> ADD >				SEP 24, 1986	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

AP	STERIS	100MG/ML	N83760 001	
	@	100MG/ML	N83760 001	

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

> ADD >				
> ADD >	AB	GRANUTEC PHARMS	EQ 150MG BASE	N74488 001
> ADD >				JUL 31, 1997
> ADD >	AB		EQ 300MG BASE	N74488 002
> ADD >				JUL 31, 1997
		ZANTAC 150		
> ADD >	AB	GLAXO WELLCOME	EQ 150MG BASE	N18703 001
> ADD >				JUN 09, 1983
		ZANTAC 300		
> ADD >	AB +	GLAXO WELLCOME	EQ 300MG BASE	N18703 002
> ADD >				DEC 09, 1985

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUWOLFIA SERPENTINA

> ADD >	@	ZENITH GOLDLINE	50MG	N11521 001
> ADD >	@		100MG	N11521 002
> DLT >	@	ZENITH LABS	50MG	N11521 001
> DLT >	@		100MG	N11521 002

RESERPINE

TABLET; ORAL
RESERPINE

BP	PUREPAC PHARM	0.1MG	N80753 002	
BP		0.25MG	N80753 001	
	@	0.1MG	N80753 002	
	@	0.25MG	N80753 001	
> ADD >	@	ZENITH GOLDLINE	0.1MG	N11185 001
> ADD >	@		0.25MG	N11185 002
> DLT >	@	ZENITH LABS	0.1MG	N11185 001
> DLT >	@		0.25MG	N11185 002

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN

AB	EON	300MG	N64150 001	
			MAY 28, 1997	

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET

CYTOGEN	50mCi/ML	N20570 001	
		MAR 28, 1997	

SECOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM SECOBARBITAL

AA	HALSEY	100MG	N84676 001	
	@	100MG	N84676 001	

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

		ELDEPRYL			
AB	+	SOMERSET	5MG	N20647 001	
				MAY 15, 1996	
	+		5MG	N20647 001	
				MAY 15, 1996	

TABLET; ORAL

	SELEGILINE HCL			
AB	APOTEX	5MG	N74871 001	
			JUN 06, 1997	
AB	APOTHECON	5MG	N74672 001	
			APR 01, 1997	
AB	TEVA	5MG	N74744 001	
			JAN 27, 1997	

SODIUM IODIDE, I-123

CAPSULE; ORAL

		SODIUM IODIDE I 123			
>DLT<	AA	GOLDEN PHARMS	100 uCi	N18671 001	
>DLT<				MAY 27, 1982	
>DLT<	AA		200 uCi	N18671 002	
>DLT<				MAY 27, 1982	
>ADD<	AA	SYNCOR	100 uCi	N18671 001	
>ADD<				MAY 27, 1982	
>ADD<	AA		200 uCi	N18671 002	
>ADD<				MAY 27, 1982	

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

		NITROPRESS			
AP		ABBOTT	50MG/VIAL	N71555 001	
				NOV 16, 1987	
	@		50MG/VIAL	N71555 001	
				NOV 16, 1987	

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION

		NORDITROPIN			
>ADD<	BX	+ NOVO NORDISK	4MG/VIAL	N19721 001	
>ADD<				MAY 08, 1995	

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION

		SEROSTIM			
>ADD<	BX	SERONO	4MG/VIAL	N20604 003	
>ADD<				JUL 25, 1997	

SULFAMETHOXAZOLE

SUSPENSION; ORAL

	GANTANOL			
	+ ROCHE	500MG/5ML	N13664 002	
	@	500MG/5ML	N13664 002	

SULFISOXAZOLE

TABLET; ORAL

		SULFISOXAZOLE			
>DLT<	AB	PUREPAC PHARM	500MG	N80087 001	
>ADD<		@	500MG	N80087 001	

TAMOXIFEN CITRATE

TABLET; ORAL

		NOLVADEX			
>DLT<		+ ZENECA	EQ 10MG BASE	N17970 001	
>ADD<			EQ 10MG BASE	N17970 001	

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

	FLOMAX			
	+ BOEHRINGER INGELHEIM	0.4MG	N20579 001	
			APR 15, 1997	

TAZAROTENE

GEL; TOPICAL

TAZORAC			
ALLERGAN	0.05%	N20600 001	
		JUN 13, 1997	
+	0.1%	N20600 002	
		JUN 13, 1997	

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

		MDP-BRACCO		
AP		BRACCO	**N/A**	**N18107 001**
		MDP-SQUIBB		
AP		BRACCO	**N/A**	**N18107 001**

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

> ADD >		MIRALUMA		
> ADD >		DUPONT	N/A	N19785 003
> ADD >				MAY 23, 1997

TERFENADINE

TABLET; ORAL

		SELDANE		
AB	+	HOECHST MARION RSSL	**60MG**	**N18949 001**
				MAY 08, 1985
		TERFENADINE		
AB		BAKER NORTON	**60MG**	**N74475 001**
				JAN 03, 1997

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

		TETRACYCLINE HCL		
AB		WARNER CHILCOTT	**250MG**	**N62300 001**
AB			**500MG**	**N62300 002**
	@		250MG	N62300 001
	@		500MG	N62300 002

INJECTABLE; INJECTION

		ACHROMYCIN		
AP	+	LEDERLE	**250MG/VIAL**	**N50273 002**
AP			**500MG/VIAL**	**N50273 003**
	+		250MG/VIAL	N50273 002
			500MG/VIAL	N50273 003
		TETRACYN		
AP		PFIZER	**250MG/VIAL**	**N60096 001**
AP			**500MG/VIAL**	**N60096 002**
	@		250MG/VIAL	N60096 001
	@		500MG/VIAL	N60096 002

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

		TETRACYCLINE HCL		
AB		ALPHARMA	**125MG/5ML**	**N60633 001**
	@		125MG/5ML	N60633 001
AB		PUREPAC PHARM	**125MG/5ML**	**N60291 001**
	@		125MG/5ML	N60291 001
		TETRACYN		
AB		PFIPHARMECS	**125MG/5ML**	**N60095 001**
	@		125MG/5ML	N60095 001

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

		THALLOUS CHLORIDE TL 201		
AP		DUPONT	**1mCi/ML**	**N17806 001**
AP	+		**1mCi/ML**	**N17806 001**
AP		MALLINCKRODT	**1mCi/ML**	**N18150 001**
AP	+		**1mCi/ML**	**N18150 001**
AP	+	MEDI PHYSICS	**1mCi/ML**	**N18110 002**
				FEB 27, 1996
			1mCi/ML	N18110 002
				FEB 27, 1996

THEOPHYLLINE

CAPSULE; ORAL

		BRONKODYL		
BP		STERLING WINTHROP	100MG	N85264 001
BP			200MG	N85264 002
	@		100MG	N85264 001
	@		200MG	N85264 002
		THEOPHYLLINE		
BP		KV PHARM	100MG	N85263 001
BP			200MG	N85263 002
	@		100MG	N85263 001
	@		200MG	N85263 002

CAPSULE, EXTENDED RELEASE; ORAL

		SOMOPHYLLIN-CRT		
BC		GRAHAM DM	50MG	N87763 001
				FEB 27, 1985
BC			100MG	N87194 001
BC			200MG	N88382 001
				FEB 27, 1985
BC			250MG	N87193 001

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	SOMOPHYLLIN-CRT				
BC	GRAHAM DM	300MG	N88383 001 FEB 27, 1985		
	@	50MG	N87763 001 FEB 27, 1985		
	@	100MG	N87194 001		
	@	200MG	N88382 001 FEB 27, 1985		
	@	250MG	N87193 001		
	@	300MG	N88383 001 FEB 27, 1985		

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	THIAMINE HCL				
AP	STERIS	100MG/ML	N83534 001		
		200MG/ML	N83534 002		
	@	100MG/ML	N83534 001		
	@	200MG/ML	N83534 002		

TILUDRONATE DISODIUM

TABLET; ORAL

	SKELID				
+	SANOFI	EQ 200MG BASE	N20707 001 MAR 07, 1997		

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

	BETIMOL				
+	LEIRAS	EQ 0.25% BASE	N20439 001 MAR 31, 1995	> DLT >	> DLT >
+		EQ 0.5% BASE	N20439 002 MAR 31, 1995	> ADD >	> ADD >
+	OY STAR	EQ 0.25% BASE	N20439 001 MAR 31, 1995		
+		EQ 0.5% BASE	N20439 002 MAR 31, 1995		

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE				
AT	ADV REMEDIES	EQ 0.25% BASE	N74465 001 MAR 25, 1997		
AT		EQ 0.5% BASE	N74466 001 MAR 25, 1997		
AT	AKORN	EQ 0.25% BASE	N74515 001 MAR 25, 1997		
AT		EQ 0.5% BASE	N74516 001 MAR 25, 1997		
AT	BAUSCH AND LOMB	EQ 0.25% BASE	N74778 001 MAR 25, 1997		
AT		EQ 0.5% BASE	N74776 001 MAR 25, 1997		
AT	FOUGERA	EQ 0.25% BASE	N74667 001 MAR 25, 1997		
AT		EQ 0.5% BASE	N74668 001 MAR 25, 1997		
AT	PACIFIC PHARMA	EQ 0.25% BASE	N74746 001 MAR 25, 1997		
AT		EQ 0.5% BASE	N74747 001 MAR 25, 1997		

TIOCONAZOLE

OINTMENT; VAGINAL

	VAGISTAT-1				
+	BRISTOL MYERS	6.5%	N19355 001 DEC 30, 1986		

TOLBUTAMIDE

TABLET; ORAL

	TOLBUTAMIDE				
AB	PUREPAC PHARM	500MG	N88950 001 JUN 17, 1985		
	@	500MG	N88950 001 JUN 17, 1985		

TOLMETIN SODIUM

TABLET; ORAL

	TOLMETIN SODIUM				
AB	BAKER NORTON	EQ 600MG BASE	N74399 001 MAR 28, 1996		

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM

AB	LEMMON	EQ 600MG BASE	N74729 001 FEB 27, 1997
	@ TEVA	EQ 600MG BASE	N74729 001 FEB 27, 1997
AB	ZENITH GOLDLINE	EQ 600MG BASE	N74399 001 MAR 28, 1996

TOPIRAMATE

TABLET; ORAL
TOPAMAX

	@ JOHNSON RW	400MG	N20505 006 DEC 24, 1996

TOREMIFENE CITRATE

TABLET; ORAL
FARESTON

	+ ORION	EQ 60MG BASE	N20497 001 MAY 29, 1997

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL

AB	TEVA	150MG	N74357 001 APR 30, 1997

TRETINOIN

CREAM; TOPICAL
AVITA

AB	PENEDERM	0.025%	N20404 003 JAN 14, 1997

RETIN-A

AB	+ J AND J	0.025%	N19049 001 SEP 16, 1988

GEL; TOPICAL
RETIN-A MICRO

	+ ADV POLYMER	0.1%	N20475 001 FEB 07, 1997

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE

BP	PUREPAC PHARM	2MG	N84020 002
BP		4MG	N84020 003
	@	2MG	N84020 002
	@	4MG	N84020 003

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	ALPHARMA	0.1%	N87192 001 SEP 08, 1982
	@	0.1%	N87192 001 SEP 08, 1982

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
TRIAMCINOLONE DIACETATE

BP	STERIS	40MG/ML	N85529 001
	@	40MG/ML	N85529 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	MYLAN	EQ 1MG BASE	N40209 001 JUL 07, 1997
AB		EQ 2MG BASE	N40209 002 JUL 07, 1997
AB		EQ 5MG BASE	N40209 003 JUL 07, 1997
AB		EQ 10MG BASE	N40209 004 JUL 07, 1997

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ARTANE

	+ LEDERLE	5MG	N12947 001
	@	5MG	N12947 001

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

	TRIHEXYPHENIDYL HCL				
AA	PHARM ASSOC	**2MG/5ML**	**N40177 001**	> ADD >	
			APR 17, 1997	> ADD >	
				> DLT >	
				> DLT >	

TRIMETHOPRIM

TABLET; ORAL

	PROLOPRIM		
AB	GLAXO WELLCOME	**200MG**	**N17943 003**
			JUL 14, 1982
AB +		**200MG**	**N17943 003**
			JUL 14, 1982
	TRIMPEX 200		
AB +	ROCHE	**200MG**	**N17952 002**
			NOV 09, 1982
	@	200MG	N17952 002
			NOV 09, 1982

TROGLITAZONE

TABLET; ORAL

	PRELAY		
AB	SANKYO	**200MG**	**N20719 001**
			JAN 29, 1997
AB		**400MG**	**N20719 002**
			JAN 29, 1997
	REZULIN		
AB	PARKE DAVIS	**200MG**	**N20720 001**
			JAN 29, 1997
AB		**400MG**	**N20720 002**
			JAN 29, 1997

UREA C-14

CAPSULE; ORAL

	PYTEST		
+	TRI MED SPECLTS	1 uCi	N20617 001
			MAY 09, 1997
	PYTEST KIT		
+	TRI MED SPECLTS	1 uCi	N20617 002
			MAY 09, 1997

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	VANCOCIN HCL IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N50671 001
			APR 29, 1993
+	**LILLY**	**EQ 500MG BASE/100ML**	**N50671 001**
			APR 29, 1993

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	ISOPTIN SR		
AB +	KNOLL PHARM	**120MG**	**N19152 003**
			MAR 06, 1991
	VERAPAMIL HCL		
AB	MYLAN	**120MG**	**N74587 002**
			FEB 21, 1997

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCREX		
AP +	BRISTOL MYERS	**5MG/VIAL**	**N70867 001**
			JUL 12, 1988
	@ BRISTOL MYERS SQUIBB	5MG/VIAL	N70867 001
			JUL 12, 1988
	VINCRISTINE SULFATE		
AP	FAULDING	**5MG/VIAL**	**N71561 001**
			APR 11, 1988
+		5MG/VIAL	N71561 001
			APR 11, 1988

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN		
AB	DUPONT MERCK	**1MG**	**N09218 022**
			MAR 01, 1990
AB +		**2MG**	**N09218 013**
AB		**2.5MG**	**N09218 018**
AB		**4MG**	**N09218 023**
			AUG 24, 1993
AB		**5MG**	**N09218 007**
AB		**7.5MG**	**N09218 016**
AB +		**10MG**	**N09218 005**

WARFARIN SODIUM

TABLET; ORAL

	WARFARIN SODIUM		
AB	BARR	1MG	**N40145 001** MAR 26, 1997
AB		2MG	**N40145 002** MAR 26, 1997
AB		2.5MG	**N40145 003** MAR 26, 1997
AB		4MG	**N40145 004** MAR 26, 1997
AB		5MG	**N40145 005** MAR 26, 1997
AB		7.5MG	**N40145 006** MAR 26, 1997
AB		10MG	**N40145 007** MAR 26, 1997

ZINC ACETATE

CAPSULE; ORAL

	GALZIN		
	TEVA	EQ 25MG ZINC	N20458 001 JAN 28, 1997
+		EQ 50MG ZINC	N20458 002 JAN 28, 1997

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV

+	GRAHAM DM	12MG;75MG	N18793 001 APR 25, 1985
@		12MG;75MG	N18793 001 APR 25, 1985

COLD CAPSULE V

	GRAHAM DM	8MG;75MG	N18794 001 APR 23, 1985
@		8MG;75MG	N18794 001 APR 23, 1985

TABLET, EXTENDED RELEASE; ORAL

CONTAC

> ADD >	NOVARTIS	12MG;75MG	N19613 001 JUN 13, 1986

> ADD >
> ADD >

> DLT > PHENYLPROPANOLAMINE HCL/CHLORPHENIRAMINE

> DLT >	SANDOZ	12MG;75MG	N19613 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

> DLT > CODIMAL-L.A. 12

> DLT > +	CENT PHARMS	12MG;120MG	N18935 001 APR 15, 1985
> DLT >			
> ADD > @	SCHWARZ PHARMA	12MG;120MG	N18935 001 APR 15, 1985

> ADD >

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE

	KV PHARM	12MG;120MG	N71455 001 MAR 01, 1989
@		12MG;120MG	N71455 001 MAR 01, 1989

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

	LEMMON	1.34MG	N73282 002 DEC 03, 1992
	TEVA	1.34MG	N73282 002 DEC 03, 1992

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+	SCHERING PLOUGH	1%,200MG	N20526 002 JUL 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+	SCHERING PLOUGH	1%,100MG	N20289 002 APR 26, 1993

MYCELEX-7 COMBINATION PACK

	BAYER	1%,100MG	N20389 002 JUN 23, 1994

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+	SCHERING PLOUGH	1%,200MG	N20526 002 JUL 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+	SCHERING PLOUGH	1%,100MG	N20289 002 APR 26, 1993

MYCELEX-7 COMBINATION PACK

	BAYER	1%,100MG	N20389 002 JUN 23, 1994

SUPPOSITORY; VAGINAL

GYNE-LOTRIMIN

+	SCHERING PLOUGH	100MG	N17717 002 NOV 30, 1990

GYNE-LOTRIMIN 3

+	SCHERING PLOUGH	200MG	N20525 001 JUL 29, 1996

MYCELEX-7

	BAYER	100MG	N18182 002 DEC 26, 1991

TABLET; VAGINAL

GYNE-LOTRIMIN

+	SCHERING PLOUGH	100MG	N17717 002 NOV 30, 1990

GYNE-LOTRIMIN 3

+	SCHERING PLOUGH	200MG	N20525 001 JUL 29, 1996

MYCELEX-7

	BAYER	100MG	N18182 002 DEC 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL
NASALCROM
+ PHARMACIA AND UPJOHN 5.2MG/SPRAY — N20463 001 JAN 03, 1997 — >ADD> >ADD> >ADD> >ADD>

IBUPROFEN

TABLET; ORAL
IBUPROFEN
PUREPAC PHARM 200MG — N71122 001 OCT 03, 1986
200MG — N71664 001 FEB 03, 1987
@ 200MG — N71122 001 OCT 03, 1986
@ 200MG — N71664 001 FEB 03, 1987

JUNIOR STRENGTH MOTRIN
MCNEIL 100MG — N20602 001 JUN 10, 1996
+ 100MG — N20602 001 JUN 10, 1996

NUPRIN
@ MCNEIL 200MG — N19012 001 MAY 18, 1984 >ADD>
@ 200MG — N19012 003 JUL 29, 1987 >ADD>
@ PHARMACIA AND UPJOHN 200MG — N19012 001 MAY 18, 1984
@ 200MG — N19012 003 JUL 29, 1987

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
VELOSULIN BR HUMAN
+ NOVO NORDISK 100 UNITS/ML — N19450 001 MAY 30, 1986

VELOSULIN HUMAN
+ NOVO NORDISK 100 UNITS/ML — N19450 001 MAY 30, 1986

LOPERAMIDE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL
IMODIUM A-D
+ MCNEIL 2MG — N20448 001 JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL
IMODIUM ADVANCED
+ MCNEIL 2MG;125MG — N20606 001 JUN 26, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE
PERRIGO 2% — N74760 001 MAY 15, 1997
TARO 2% — N74444 001 JAN 13, 1997

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 7 DUAL PACK
ALPHARMA 2%,100MG — N74586 001 JUL 17, 1997

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
G AND W LABS 100MG — N74414 001 APR 30, 1997
+ PERRIGO 100MG — N74395 001 MAR 20, 1997

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
MORTON GROVE 2% — N74767 001 FEB 28, 1997

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM		
GRANUTEC	EQ 200MG BASE	N74635 001 JAN 13, 1997
INVAMED	EQ 200MG BASE	N74646 001 JAN 13, 1997
NOVOPHARM	EQ 200MG BASE	N74635 001 JAN 13, 1997
PERRIGO	EQ 200MG BASE	N74661 001 JAN 13, 1997
PVT FORM	EQ 200MG BASE	N74789 001 FEB 27, 1997

PERMETHRIN

LOTION; TOPICAL

NIX		
+ WARNER LAMBERT	1%	N19918 001 MAY 02, 1990
+ WARNER WELLCOME	1%	N19918 001 MAY 02, 1990

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES		
KV PHARM	120MG;5MG	N71798 001 MAR 16, 1989
@	120MG;5MG	N71798 001 MAR 16, 1989

> ADD > SODIUM FLUORIDE; TRICLOSAN

> ADD > PASTE; DENTAL

> ADD > COLGATE TOTAL		
> ADD > + COLGATE PALMOLIVE	0.24%;0.3%	N20231 001 JUL 11, 1997

TIOCONAZOLE

OINTMENT; VAGINAL

VAGISTAT-1		
+ BRISTOL MYERS SQUIBB	6.5%	N20676 001 FEB 11, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 7/ JULY '97

NO JULY APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1997 through July 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
15AU81 TN=	Treatment of primary pulmonary hypertension.	Lung Rx, Inc. 2 Davis Drive P.O. Box 13169 Research Triangle Park, NC 27709 DD=06/04/1997
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture TN= CYTOIMPLANT	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs, CA 90670 DD=06/13/1997
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997

Orphan Product Designations and Approvals List
January 1997 through July 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
B2036-PEG TN= Trovert	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin, TX 78701 DD=06/24/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Busulfan TN=	Treatment of primary brain malignancies.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham, PA 19044 DD=07/07/1997
CY-1503 TN= Cylexin	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court San Diego, CA 92121 DD=07/18/1997
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997

Orphan Product Designations and Approvals List
January 1997 through July 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Fampridine TN=	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 145 West 58th Sreet Suite 8J New York, NY 10019 DD=06/02/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997

Orphan Product Designations and Approvals List
January 1997 through July 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Human retinal pigmented epithelial cells on collagen microcarriers TN= Spheramine	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Theracell, Inc. 50 Division Street, Suite 503 Somerville, NJ 08876 DD=07/18/1997
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution TN= Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road Waukegan, IL 60085 DD=07/18/1997
Lepirudin TN= Refludan	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997

Orphan Product Designations and Approvals List
January 1997 through July 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corporation 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997

Orphan Product Designations and Approvals List
January 1997 through July 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue TN= N-Graft	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Theracell, Inc. 50 Division Street Suite 503 Somerville, NJ 08876 DD=06/24/1997
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=05/06/1997
Suramin TN=	Treatment of metastatic hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=05/06/1997
Toremifene TN= Fareston	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 02101 ESPOO Finland, DD=09/19/1991 MA=05/29/1997
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 1997 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN

NEW INDICATION

I-177	TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPH TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THNNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTRURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-198	TREATMENT METASTIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020059	001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
	020291	001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015		NC	OCT 24, 1999
	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5225183	JUL 06, 2010		NP	AUG 15, 1999
				5439670	JUL 06, 2010			
				5605674	FEB 25, 2014			
	020560	001	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
							I-187	APR 25, 2000
	020560	002	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
							I-187	APR 25, 2000
	020560	003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		NS	APR 25, 2000
				4621077	NOV 04, 2003	U-114	I-185	APR 25, 2000
							I-187	APR 25, 2000
>ADD>	020221	001	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012			
>ADD>				5591731	JUL 31, 2012			
	020333	001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
	020333	002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
	020227	002	ARDEPARIN SODIUM;NORMIFLO				NCE	MAY 23, 2002
	020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH				NP	DEC 24, 1999
	020032	001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
	020619	001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U-191	NC	APR 17, 2000
	020490	001	BRIMONIDINE TARTRATE;ALPHAGAN				NP	MAR 13, 2000
							NCE	SEP 06, 2001
>ADD>	020535	002	BROMFENAC SODIUM;DURACT				NCE	JUL 15, 2002
	020441	002	BUDESONIDE;PULMICORT	4907583	MAR 13, 2002			
				4524769	JUN 25, 2002			
				4668218	APR 11, 2006			
	020441	003	BUDESONIDE;PULMICORT	4907583	MAR 13, 2002			
				4524769	JUN 25, 2002			
				4668218	APR 11, 2006			
	018644	002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	018644	003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
				5427798	AUG 12, 2013			
				RE33994	AUG 18, 2004			
	020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
				5427798	AUG 12, 2013			
				RE33994	AUG 18, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	JUN 04, 2008	U-177		
	019881	001	BUTOCONAZOLE NITRATE;FEMSTAT ONE	4078071	MAR 07, 1997		NP	FEB 07, 2000
	020664	001	CABERGOLINE;DOSTINEX	4526892	JUL 02, 2002		NCE	DEC 23, 2001
	020273	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007		D-33	MAR 20, 2000
	020554	001	CALCIPOTRIENE;DOVONEX				NCE	DEC 29, 1998
	020611	001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006		NDF	MAR 03, 2000
							NCE	DEC 29, 1998
	019880	001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880	002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880	003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
>ADD>	020297	001	CARVEDILOL;COREG				I-194	MAY 29, 2000
>ADD>	020297	002	CARVEDILOL;COREG				I-194	MAY 29, 2000
>ADD>	020297	003	CARVEDILOL;COREG				I-194	MAY 29, 2000
>ADD>	020297	004	CARVEDILOL;COREG				I-194	MAY 29, 2000
	020740	001	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
	020740	002	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
	020740	003	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
	020740	004	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
	019835	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	019835	002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	020346	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
>ADD>	020519	001	CICLOPIROX;LOPROX				NDF	JUL 21, 2000
	019537	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011		I-188	JUN 03, 2000
				4670444	DEC 09, 2003	U-36		
	019537	002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
	019537	003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
	019537	004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
	019847	001	CIPROFLOXACIN;CIPRO	4705789	NOV 10, 2004		I-179	OCT 21, 1999
	019857	001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4808583	FEB 28, 2006		I-179	OCT 21, 1999
	019858	001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4705789	NOV 10, 2004		I-179	OCT 21, 1999
	017533	001	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	002	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	003	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	005	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	006	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	020463	001	CROMOLYN SODIUM;NASALCROM				NP	JAN 03, 2000
	020430	001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
	020705	001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013		NCE	APR 04, 2002
>ADD>	017922	001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
>ADD>				5482931	JUN 29, 2013			
>ADD>	017922	002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
>ADD>				5482931	JUN 29, 2013			
>ADD>	018938	001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
>ADD>	018938	002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
>ADD>	019955	001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
>ADD>	019955	002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
>ADD>	020648	001	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
>ADD>							ODE	JUL 29, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020648	002	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
>ADD>							ODE	JUL 29, 2004
>ADD>	020648	003	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
>ADD>							ODE	JUL 29, 2004
>ADD>	020648	004	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
>ADD>							ODE	JUL 29, 2004
>ADD>	020648	005	DIAZEPAM;DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
>ADD>							ODE	JUL 29, 2004
	020037	001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
				4829088	APR 14, 2007			
	020154	002	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020154	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020154	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
	020154	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
	020156	001	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	018723	001	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	018723	002	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	018723	003	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	019680	001	DIVALPROEX SODIUM;DEPAKOTE	4988731	JAN 29, 2008		I-181	JUN 20, 1999
	020668	001	ENALAPRIL MALEATE;LEXXEL	4472380	SEP 18, 2001			
				4374829	DEC 30, 2001	U-3		
				4703038	OCT 07, 2005	U-3		
>ADD>	020164	001	ENOXAPARIN SODIUM;LOVENOX				I-192	MAY 06, 2000
	020444	001	EPOPROSTENOL SODIUM;FLOLAN	4335139	JUN 15, 1999			
				4539333	SEP 03, 2002			
				4883812	MAY 12, 2006	U-185		
				4338325	JUL 06, 1999			
	020444	002	EPOPROSTENOL SODIUM;FLOLAN	4539333	SEP 03, 2002			
				4338325	JUL 06, 1999			
				4883812	MAY 12, 2006	U-185		
				4335139	JUN 15, 1999			
	020417	001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007		NP	DEC 03, 1999
				5006342	APR 09, 2008			
>ADD>	020683	001	ETHINYL ESTRADIOL;ALESSE				NP	MAR 27, 2000
>ADD>	020683	002	ETHINYL ESTRADIOL;ALESSE				NP	MAR 27, 2000
	019697	001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	019697	002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	018922	005	ETODOLAC;LODINE				I-24	JUN 28, 1999
>ADD>	020457	001	ETOPOSIDE PHOSPHATE;ETOPOPHOS	RE35524	AUG 04, 2007			
>DLT>	020457	001	ETOPOSIDE PHOSPHATE;ETOPOPHOS	4904768	FEB 27, 2007			
	020410	001	FERUMOXSIL;GASTROMARK	5069216	MAY 09, 2006	U-171	NCE	DEC 06, 2001
				5219554	JUN 15, 2010			
				4827945	MAY 09, 2006	U-170		
				4951675	SEP 13, 2005	U-169		
				5055288	OCT 08, 2008			
				4695392	SEP 22, 2004			
				4695393	SEP 22, 2004			
				4770183	SEP 13, 2005	U-169		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020625	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-192		
	020038	001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	FEB 24, 2003			
	020235	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
	020235	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
	020235	003	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008			
				4087544	JAN 16, 2000	U-86		
							ODE	DEC 20, 2003
	020622	001	GLATIRAMER ACETATE;COPAXONE					
	020329	001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
	020329	002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
>ADD>	019726	001	GOSERELIN ACETATE;ZOLADEX				I-191	JUN 27, 2000
>ADD>	020504	001	HYDROCHLOROTHIAZIDE;MICROZIDE				NS	DEC 27, 1999
>ADD>	020729	001	HYDROCHLOROTHIAZIDE;UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
				4743450	FEB 24, 2007			
>ADD>	020729	002	HYDROCHLOROTHIAZIDE;UNIRETIC	4344949	OCT 03, 2000		NC	JUN 27, 2000
				4743450	FEB 24, 2007			
	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
	020723	001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2004	U-172	NCE	FEB 27, 2002
				5238944	AUG 24, 2010			
	040024	001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
	020083	001	ITRACONAZOLE;SPORANOX				I-178	DEC 06, 1999
	020657	001	ITRACONAZOLE;SPORANOX				NDF	FEB 21, 2000
	019927	001	KETOCONAZOLE;NIZORAL				I-186	MAY 30, 2000
>ADD>	020406	001	LANSOPRAZOLE;PREVACID				I-195	JUN 17, 2000
>ADD>							I-196	MAY 08, 2000
>ADD>							I-197	APR 17, 2000
>ADD>							I-198	JUN 17, 2000
>ADD>	020406	002	LANSOPRAZOLE;PREVACID				I-195	JUN 17, 2000
>ADD>							I-196	MAY 08, 2000
>ADD>							I-197	APR 17, 2000
>ADD>							I-198	JUN 17, 2000
>ADD>	020726	001	LETROZOLE;FEMARA				NCE	JUL 25, 2002
>ADD>	020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5643607	JUL 01, 2014		NP	MAR 07, 2000
				4652411	NOV 01, 2004			
				4677191	JUL 03, 2005			
				4728721	MAY 01, 2006			
				4849228	JUL 18, 2006			
				4917893	NOV 01, 2004			
				4954298	NOV 01, 2004			
				5330767	NOV 01, 2004			
				5476663	APR 17, 2007			
				5480656	JAN 02, 2013			
				5575987	NOV 19, 2013			
				5631020	MAY 20, 2014			
				5631021	MAY 20, 2014			
				4652441	NOV 01, 2004			
>ADD>	019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JUL 01, 2014			
				5631020	MAY 20, 2014			
				5631021	MAY 20, 2014			
				4954298	NOV 01, 2004			
				5480656	JAN 02, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JUL 01, 2014			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
			4954298	NOV 01, 2004			
			5480656	JAN 02, 2013			
>ADD>	020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JUL 01, 2014			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
>ADD>	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5643607	JUL 01, 2014		NS	MAY 30, 2000
>ADD>			4677191	JUL 03, 2005		D-34	MAY 30, 2000
			4728721	MAY 01, 2006			
			4849228	JUL 18, 2006			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
			4652411	NOV 01, 2004			
			5476663	APR 17, 2007			
			5480656	JAN 02, 2013			
			5575987	NOV 19, 2013			
			4917893	NOV 01, 2004			
			4954298	NOV 01, 2004			
			5330767	NOV 01, 2004			
>ADD>	020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
			5480656	JAN 02, 2013			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
			4954298	NOV 01, 2004			
>ADD>	020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
			5480656	JAN 02, 2013			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
			4954298	NOV 01, 2004			
>ADD>	020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
			5480656	JAN 02, 2013			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
			4954298	NOV 01, 2004			
>ADD>	020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
			5480656	JAN 02, 2013			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
			4954298	NOV 01, 2004			
>ADD>	020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5643607	JUL 01, 2014			
			5480656	JAN 02, 2013			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
			4954298	NOV 01, 2004			
>ADD>	020580 001	LIPASE;COTAZYM				NP	DEC 09, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	JUL 28, 2010		NC	JUN 26, 2000
>ADD>				5612054	SEP 28, 2010			
	020641	001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
	020704	001	LORATADINE;CLARITIN REDITABS	4282233	JUN 19, 2002	U-77	NCE	APR 12, 1998
				4659716	APR 21, 2004	U-142		
	020357	001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020357	002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
>ADD>	020689	001	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
>ADD>	020689	002	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	4808605	NOV 10, 2007	U-194	NCE	JUN 20, 2002
	019297	001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	2222222	SEP 05, 1997			
	020353	001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
	020353	002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
	020353	003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
	019660	001	NEDOCROMIL SODIUM;TILADE				I-183	MAR 06, 2000
	020778	001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
	020779	001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
	020636	001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167	NCE	JUN 21, 2001
>ADD>	020381	001	NIACIN;NIASPAN				NDF	JUL 28, 2000
>ADD>	020381	002	NIACIN;NIASPAN				NDF	JUL 28, 2000
>ADD>	020381	003	NIACIN;NIASPAN				NDF	JUL 28, 2000
>ADD>	020381	004	NIACIN;NIASPAN				NDF	JUL 28, 2000
>ADD>	020381	005	NIACIN;NIASPAN TITRATION STARTER PAC				NDF	JUL 28, 2000
	020714	001	NICOTINE;NICOTROL				NP	MAY 02, 2000
	020592	001	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	002	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	003	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	004	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	4871865	OCT 03, 2006			
				4923892	MAY 08, 2007	U-174		
				5116863	MAY 26, 2009			
				5641805	JUN 24, 2014	U-184		
	019810	001	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
				5629305	FEB 04, 2014	U-188		
	019810	003	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
				5629305	FEB 04, 2014	U-188		
	020605	001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
				4695578	JUN 25, 2005	U-183		
				5578628	JUN 24, 2006	U-44		
>ADD>	020262	001	PACLITAXEL;TAXOL	5641803	AUG 03, 2012	U-198		
	020031	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020031	005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
>ADD>	020710	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAR 07, 1999
>ADD>							NCE	DEC 29, 1997
>ADD>	019385	001	PERGOLIDE MESYLATE;PERMAX	4180582	FEB 08, 1998	U-20		
				5114948	OCT 19, 2009			
>ADD>	019385	002	PERGOLIDE MESYLATE;PERMAX	4180582	FEB 08, 1998	U-20		
				5114948	OCT 19, 2009			
>ADD>	019385	003	PERGOLIDE MESYLATE;PERMAX	4180582	FEB 08, 1998	U-20		
				5114948	OCT 19, 2009			
	018796	001	PILOCARPINE HYDROCHLORIDE;PILOPINE HS	4271143	MAY 09, 1999			
	020529	001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004		NDF	MAR 13, 2000
				5057616	OCT 15, 2008			
>ADD>	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
>ADD>	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
>ADD>	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
>ADD>	020667	004	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
>ADD>	020667	005	PRAMIPEXOLE DIHYDROCHLORIDE HYDRATE;MIRAPEX	4866812	DEC 12, 2006		NCE	JUL 01, 2002
>ADD>	020701	001	PROGESTERONE;CRINONE				NP	JUL 31, 2000
>ADD>	020701	002	PROGESTERONE;CRINONE				NP	JUL 31, 2000
	020756	001	PROGESTERONE;CRINONE				NP	MAY 13, 2000
	019627	002	PROPOFOL;DIPRIVAN				NP	JUN 11, 1999
	020559	001	RANITIDINE BISMUTH CITRATE;TRITEC	5629297	MAY 13, 2014	U-186		
	020272	001	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	002	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	003	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	004	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020588	001	RISPERIDONE;RISPERDAL	5453425	JUN 11, 2014			
				5616587	JUN 11, 2014			
	020659	001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
	020680	001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5380922	JAN 10, 2012			
				5225445	FEB 12, 2008	U-182		
	020570	001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
	020570	002	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
>ADD>	019839	001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
>ADD>	019839	002	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
>ADD>	019839	003	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
>ADD>	019839	004	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
>ADD>	019839	005	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
>ADD>	020231	001	SODIUM FLUORIDE;COLGATE TOTAL				NC	JUL 11, 2000
	019640	001	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	019640	004	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	020168	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	020168	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
							I-182	DEC 30, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020579	001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181	NCE	APR 15, 2002
				4731478	OCT 27, 2004			
				4703063	OCT 27, 2004			
				4772475	FEB 27, 2006			
>ADD>	020600	001	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
>ADD>	020600	002	TAZAROTENE;TAZORAC	5089509	FEB 18, 2009	U-193	NCE	JUN 13, 2002
>ADD>	019785	003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA				I-190	MAY 23, 2000
	019057	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	020347	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3		
						U-165		
	020347	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020192	001	TERBINAFINE HYDROCHLORIDE;LAMISIL				I-180	JAN 21, 2000
	020707	001	TILUDRONATE DISODIUM;SKELID	4876248	OCT 24, 2006		NCE	MAR 07, 2002
				4980171	APR 06, 2009			
	020676	001	TIOCONAZOLE;VAGISTAT-1				NP	FEB 11, 2000
>ADD>	020497	001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2004	U-196	NCE	MAY 29, 2002
							ODE	MAY 29, 2004
	020404	003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
				5045317	SEP 03, 2008	U-179		
	020475	001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NP	FEB 07, 2000
	074374	001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL				I-189	JUN 17, 2000
	020326	001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	MAY 09, 2004			
	020719	001	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
				5104888	AUG 28, 2004			
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
				5602133	SEP 15, 2013	U-173		
	020719	002	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
				5104888	AUG 28, 2004			
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
				5602133	SEP 15, 2013	U-173		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020720	001	TROGLITAZONE;REZULIN	5457109	SEP 15, 2013	U-164	NCE	JAN 29, 2002
				5602133	SEP 15, 2013	U-173		
				5478852	SEP 15, 2013	U-163		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
	020720	002	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
>ADD>	020617	001	UREA C-14;PYTEST	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
>ADD>	020617	002	UREA C-14;PYTEST KIT	4830010	MAY 15, 2006	U-195	NCE	MAY 09, 2002
	020665	001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020665	002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020547	001	ZAFIRLUKAST;ACCOLATE	5612367	MAR 18, 2014	U-189		
				5583152	AUG 22, 2006			
	020471	001	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020471	003	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020458	001	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004
	020458	002	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004

New 18th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 80128

Charge your order. It's easy!

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Authorizing Signature) (11/97)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.